All the below links are in English.
取り急ぎ以下貼っておきます。
World Vol.51
World Vol.50
World Vol.49
World Vol.48
World Vol.47
World Vol.46
World Vol.45
World Vol.44
World Vol.43
World Vol.42
World Vol.41
タグ: 金融
U.S.A. アメリカ Vol.119（California カリフォルニア州 Vol.3: pharmaceutical corporations 製薬会社）
All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
California Vol.26 (corporations: Gilead Sciences)
上記リンク内に無い本日までのツイート
Read an open letter from our Chief Medical Officer about today's @US_FDA approval of our antiviral treatment for COVID-19. https://t.co/JAyK3zJGD7
— Gilead Sciences (@GileadSciences) October 22, 2020
The @US_FDA today approved our antiviral to treat patients with COVID-19 requiring hospitalization. Read more: https://t.co/Z5lO227KVU. pic.twitter.com/NqebDeoWBv
— Gilead Sciences (@GileadSciences) October 22, 2020
We released the following statement today related to the WHO SOLIDARITY trial for the treatment of COVID-19 https://t.co/YzAy1EgnVV.
— Gilead Sciences (@GileadSciences) October 16, 2020
.@US_FDA gave its final nod to @GileadSciences #Remdesivir for treating hospitalised Covid-19 patients. @viswanath_pilla reports. #COVI19 #CoronavirusIndia #COVIDIndia https://t.co/zX7bUsJSES
— moneycontrol (@moneycontrolcom) October 23, 2020
5 Penny Stocks To Watch After Gilead Sciences' Big Remdesivir News https://t.co/fze9H7hBwI
— EIN Presswire: Lung Cancer Newswire (@EINLungCancer) October 23, 2020
NEW: Gilead Sciences has announced that the FDA has approved remdesivir for treating COVID-19. The antiviral drug becomes the first drug to receive full approval from the FDA for treatment against the coronavirus, according to the pharmaceutical company. https://t.co/FGiIkZOtPk pic.twitter.com/m9XIdaVMsE
— WebMD (@WebMD) October 22, 2020
NEW: FDA approves remdesivir to treat Covid-19, making it the first and only drug so far to have received federal approval for the coronavirus. https://t.co/NddlmHEfOo
— MSNBC (@MSNBC) October 22, 2020
BREAKING: FDA approves first COVID-19 drug, remdesivir https://t.co/C5outLVVNF
— CBS News (@CBSNews) October 22, 2020
BREAKING: FDA approves Gilead's remdesivir as coronavirus treatment https://t.co/ryNKPD9vhB
— CNBC Now (@CNBCnow) October 22, 2020
Remdesivir receives FDA approval to treat hospitalized COVID patients @drsanjaygupta reports pic.twitter.com/OxqCn3RKdM
— The Lead CNN (@TheLeadCNN) October 22, 2020
JUST IN: The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug’s maker, Gilead Sciences, says https://t.co/8pg6cHwRoB
— CNN (@CNN) October 22, 2020
Remdesivir is the first and only fully FDA-approved drug in the U.S. for treating the coronavirus. https://t.co/dtYQNytzch
— Axios (@axios) October 22, 2020
The news has barely mentioned it, but Big Pharma company Gilead is charging $3,000 for a coronavirus drug that costs them less than $10 to produce.
Once again, they're set to profit on the people's dime.
— Robert Reich (@RBReich) October 21, 2020
NEW: Gilead Sciences just received FDA approval for remdesivir. This is the inside story of how the company prepared for the pandemic https://t.co/VPXM3GjcbM pic.twitter.com/M4vwD8lNcD
— Businessweek (@BW) October 22, 2020
FDA just approved the first COVID-19 drug AND it's from @OceansideBiz-based@GileadSciences
Details here: https://t.co/pX2vmc6ZiT?— Innovate78 (@Innovate_78) October 22, 2020
@CityofOceanside's @GileadSciences #COVID19 drug now @US_FDA approved! https://t.co/jYYZjfIVNC
— San Diego North EDC (@SDNorthEDC) October 22, 2020
https://twitter.com/SDRegionalEDC/status/1319400169650073600
Morning Bell: #ASX200 to open flat with all eyes on the #USPresidentialDebate2020 at 11am AEDT. U.S. FDA approves @GileadSciences' #COVID19 treatment. Trading ideas: $ALL, $LBY, $AIS, $NGI, $MYQ & $TSO. #ausbiz #belldirect #tradingideas https://t.co/xblREmVKkU
— Bell Direct (@belldirect) October 22, 2020
The @US_FDA has approved the first drug treatment for #COVID19 in the US, and antiviral by @GileadSciences #remdesivir https://t.co/lrYd1NB3gq pic.twitter.com/byXuRUa4Pe
— Pharmacy Times (@Pharmacy_Times) October 22, 2020
.@US_FDA approves @GileadSciences's remdesivir as the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.https://t.co/QbzL80S6oN #optometry #COVID19 #remdesivir pic.twitter.com/rcDZewIRgk
— Optometry Times (@OptometryTimes) October 22, 2020
#BREAKING Remdesivir becomes first FDA fully-approved coronavirus treatment https://t.co/VAwD4PgPZI
— KTNV 13 Action News (@KTNV) October 22, 2020
Thank you to @GileadSciences for choosing PPD to help support the clinical development program of your important new COVID-19 treatment. https://t.co/xuzXL3Cqpy#ppd #covid19 #coronavirus #pandemic #followthescience #wereinthistogether #wegotthis #relentless #collaborate pic.twitter.com/81yZNEFNcC
— PPD (@PPDCRO) October 22, 2020
ICYMI: The FDA approved Remdesivir for the treatment of coronavirus infection, says the drug's maker, Gilead Sciences. https://t.co/TMDKdaRrw4
— CBS46 (@cbs46) October 23, 2020
JUST IN: The FDA has approved Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus. Remdesivir is now the first and only fully approved treatment in the U.S. https://t.co/tdD2A5IkDB
— NBC Bay Area (@nbcbayarea) October 22, 2020
The FDA has approved #remdesivir for the treatment of #COVID19, Bay Area-based Gilead Sciences, said Thursday. https://t.co/Wix6PGn7vw
— ABC7 News (@abc7newsbayarea) October 22, 2020
JUST IN: The FDA has officially approved remdesivir as a treatment for coronavirus, drug manufacturer Gilead Sciences announced.https://t.co/MZtO88r2eS
— New York Daily News (@NYDailyNews) October 22, 2020
The @NIH has paused a phase 3 study on @LillyPad’s #Covid19antibody treatment on a potential safety concern. The #NIH-sponsored study is testing bamlanivimab (LYCoV555) in combination with @GileadSciences’s #Remdesivir in hospitalized patients. https://t.co/bip662pVW9
— CHEManager International (@CHEManager_EU) October 22, 2020
.@GileadSciences’ Remdesivir Flunks WHO Trial, Gains “Prequalified” Status. Learn more:https://t.co/4LWvAJnhMb pic.twitter.com/xDLUSFqesK
— Genetic Engineering & Biotechnology News (@GENbio) October 19, 2020
News for #pharma #marketers: Mon, Oct 19
-More than 25% of state legislators accepted pharma campaign contributions since 2019
– @Pfizer won’t seek emergency authorization of vaccine until late Nov.
– @GileadSciences Remdesivir failed to prevent deathshttps://t.co/IAaXOVHudQ— MM+M Magazine (@MMMnews) October 19, 2020
ICYMI: Future of Gilead's #remdesivir for COVID-19 in doubt after WHO reveals trial data @GileadSciences #covid19 #WHOhttps://t.co/4j6ij1AD6j pic.twitter.com/Ex8jNDr631
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
WHO trial shows @GileadSciences Veklury (remdesivir) has no effect on mortality and hospital stay in COVID-19 – data is inconsistent with US studies used to support Emergency Use Authorization https://t.co/4LZOdhzd8J
— pharmaphorum (@pharmaphorum) October 16, 2020
Results from the WHO’s highly anticipated Solidarity trial found that none of the treatments ‘substantially affected mortality’ or reduced the need to ventilate patients, according to a copy of the study seen by the FT https://t.co/yuKtO8sojn pic.twitter.com/LegWL7ryGI
— Financial Times (@FinancialTimes) October 15, 2020
The US Food and Drug Administration has approved the first drug to treat COVID-19 – Remdesivir. Gilead Sciences Inc says the antiviral medicine, given through an IV for patients needing hospitalisation, cut the time for recovery by five days — from 15 days to 10 on average. pic.twitter.com/gJ5TfeROoY
— Jamaica Gleaner (@JamaicaGleaner) October 22, 2020
@US_FDA approves Gilead’s Remdesivir to treat #COVID19, even though @WHO's study found drug not effective @DrTedros @realDonaldTrump @JoeBiden @KamalaHarris @Mike_Pence @CDCgov @AfricaCDC @NIH @GileadSciences #Election2020 https://t.co/AxP8HjKLz0 via @todaynewsafrica
— TODAY NEWS AFRICA (@todaynewsafrica) October 22, 2020
Investors betting on big profits from #COVID19 treatments may get an unwelcome surprise when @GileadSciences reports quarterly results this month as remdesivir, the first important coronavirus treatment, has not been used as much as first expected. https://t.co/R9ywTIGL7T pic.twitter.com/aiINMXzsuE
— Arab News Japan (@ArabNewsjp) October 17, 2020
FDA approves Gilead Sciences' antiviral drug for treating patients hospitalized with COVID-19. https://t.co/RMKapXSqij
— Arutz Sheva (@ArutzSheva_En) October 22, 2020
Remdesivir has very little effect on Covid-19 mortality, WHO finds https://t.co/ehhGOoTtVV
— The Guardian (@guardian) October 16, 2020
So, has #remdesivir shown a survival benefit? I remember @icer_review suggested that without a survival benefit the price should be about $310. The drug costs $3,120 now. Am I missing something or are we getting price-gouged (again) by @GileadSciences?
— Gregg Gonsalves (@gregggonsalves) October 16, 2020
Gilead received the Solidarity manuscript ruling out a big impact from remdesivir on #covid19 mortality on 28 September according to @WHO.
On 8 October, before the results became public, Gilead signed a billion dollar deal with the EU Commission for remdesivir.
I have questions
— Kai Kupferschmidt (@kakape) October 16, 2020
As #IDWeek2020 spotlights the impact of the #COVID19 pandemic on fighting #HIV, learn how our CARES Grantee Fund is supporting community organizations during this difficult time.
— Gilead Sciences (@GileadSciences) October 22, 2020
The data presented at #IDWeek2020 highlight our commitment and efforts to assess and address unmet needs in #HIV treatment. Learn more here: https://t.co/7p4UfPVE9v pic.twitter.com/OCWbVbaH99
— Gilead Sciences (@GileadSciences) October 21, 2020
#HIV is not a crime. Those living with and at risk for HIV are often held back by laws that discourage people from getting tested or treated.
Learn more from Health Not Prisons Collective, who joined the panel discussion at #2020USCHA.
— Gilead Sciences (@GileadSciences) October 20, 2020
#HealthDisparities can prevent access to HIV care and treatment in Black communities. Progress in ending the #HIV epidemic means not leaving anyone behind.
Join our conversation at #2020USCHA around ending health disparities in HIV.
— Gilead Sciences (@GileadSciences) October 19, 2020
“Peer-to-peer programs work because there’s nothing unreal about it. It’s raw and it’s truth.” Tune in to the #Hepcast, made in collaboration with @Hep_Alliance, to hear how Tony McClure of @HepatitisCTrust helps engage people living with #hepatitisC.
— Gilead Sciences (@GileadSciences) October 16, 2020
This National Latinx AIDS Awareness Day, meet Bamby Salcedo, founder of @TransLatina_C and an advocate for #HIV awareness and prevention. #NLAAD
— Gilead Sciences (@GileadSciences) October 15, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Japan's health ministry included dexamethasone as an option for treatment along with Gilead Sciences Inc's antiviral drug remdesivir. #Japan #Coronavirus #CoronavirusVaccine https://t.co/VM96hBlMJo
— IndiaToday (@IndiaToday) July 22, 2020
Japan on Thursday approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, making it the country's first officially authorized drug to tackle the coronavirus disease. https://t.co/oZggDtgDyq
— GMA News (@gmanews) May 7, 2020
Japan approves Gilead Sciences' remdesivir as COVID-19 drug https://t.co/EP6Brqywfb pic.twitter.com/7UeR0czgl2
— Reuters (@Reuters) May 7, 2020
Japan approves Gilead Sciences' #Remdesivir as #COVID19 drug. $GILD https://t.co/lJeYKLbitp
— Bio Stocks™ (@BioStocks) May 7, 2020
"Japan on Saturday began to fast-track the approval of remdesivir, Gilead Sciences' antiviral drug intended to treat coronavirus patients… It has also asked the U.S. to ensure Japan receives adequate supplies of the drug."https://t.co/bqxF9ODV9I
— DUTERTENOMICS (@Dutertenomics) May 2, 2020
https://twitter.com/FinancialTimes/status/1258289223121043456
#SunStarWorldNews
TOKYO — Japan has approved Gilead Sciences’ antiviral drug remdesivir for coronavirus treatment in a fast-track review just four days after the US company submitted an application.https://t.co/YoDxFOMWR4— Sun Star Davao (@SunStarDavao) May 8, 2020
U.S. drugmaker Gilead has an experimental antiviral drug that may work against the coronavirus. It's unapproved for use in humans, but hey it appears to have worked on the first U.S. infection case in Washington state.@joewalkerWSJ https://t.co/zjXUG7rAJY
— Jonathan Cheng (@JChengWSJ) February 1, 2020
Gilead Sciences and Japan Tobacco signed a letter of intent to dissolve their licensing partnership, the cigarette company said Monday, as the U.S. drugmaker prepares to market a new HIV treatment in Japan on its own. https://t.co/WhK2ynVZpX MT @NAR pic.twitter.com/WnfoUz4J9d
— HIV Insight (@HIV_Insight) September 1, 2018
Gilead and Eisai announce co-promotion agreement for investigational rheumatoid arthritis treatment in Japan: https://t.co/ia8aFkxONY.
— Gilead Sciences (@GileadSciences) December 24, 2019
SFBN Feed: Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis: FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today … #BayArea #Biotech https://t.co/y7JaL4nXwM
— San Francisco Biotechnology Network (@sfbionetwork) September 25, 2020
Gilead Sciences and Eisai Agreed on Distribution and Co-Promotion of Filgotinib – https://t.co/xHtO20gxBa pic.twitter.com/8XM09CgNkO
— GMPnews.Net (@GMPnewsNet) December 30, 2019
Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan @GileadSciences @EisaiUS
https://t.co/92Bp0R5v30— PharmaShots – Incisive news in 3 shots (@Pharmashot) December 26, 2019
U.S.A. アメリカ Vol.118（Illinois イリノイ州 Vol.2: pharmaceutical corporations 製薬会社）
All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
Illinois Vol.11 (corporations: AbbVie)
上記リンク内に無い本日までのツイート
“The beauty of science and medicine is that it is always growing and changing.” Learn what Margot Goodkin on our #ophthalmology clinical development team sees for patients with eye diseases: https://t.co/lfDrwJ1iiA #ScientistsRock pic.twitter.com/DwOiLeQJg6
— AbbVie (@abbvie) October 21, 2020
JUST IN: This morning we announced our @US_FDA and @EMA_News submission in #atopicdermatitis. Learn more: https://t.co/GqBWMkeKiV pic.twitter.com/sf9q9SnSC8
— AbbVie (@abbvie) October 19, 2020
The future of #rheumatology? With a greater understanding of the disease, more people with #RA could have a chance for remission. Read more: https://t.co/F05zmsv9XH pic.twitter.com/TNyEYVpVgg
— AbbVie (@abbvie) October 19, 2020
Read about our combination treatment, which has been granted full approval by the @US_FDA for newly-diagnosed acute myeloid leukemia patients who are ineligible for intensive chemotherapy due to age or comorbidities. https://t.co/E4kEza2Wd2 pic.twitter.com/tbmzfu5A4v
— AbbVie (@abbvie) October 17, 2020
Itchy skin, a symptom of atopic dermatitis – also known as eczema – can cause sleep disruption and lead to symptoms of depression and anxiety. Learn more about this chronic skin condition: https://t.co/zAGqUTbgzf#unhideECZEMA #EczemaAwarenessMonth pic.twitter.com/oD17x7CgQQ
— AbbVie US (@AbbVieUS) October 21, 2020
https://twitter.com/AbbVie_AU/status/1318303724301963264
#Google Spinoff #CalicoLifeSciences Enters its First Clinical Trial with #AbbVie Cancer Drug ABBV-CLS-S579 https://t.co/H7N9CjBX2J #clinicaltrials #cancerdrugs #healthcare #abbvclss579
— TrialSite News (@TrialsiteN) October 22, 2020
In September, $IMAB licensed rights for its anti-CD47 inhibitor to AbbVie. Brad Loncar writes about the deal and what he thinks this means for the CD47 space at large. https://t.co/X11lOh4FTG pic.twitter.com/Dy2Bb9seSh
— Loncar Biotech ETFs (@LoncarFunds) October 21, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis >>RFP@ bd@mellalta.com> #mellaltameethttps://t.co/HY4h36kXa0
— Mellalta Meets (@mellaltameets) October 21, 2020
AbbVie’s Allergan Aesthetics brand gets a facelift https://t.co/BzvtfloRcG
— cafepharma (@cafepharma) October 21, 2020
#AbbVie Announces Commencement of Registered Exchange Offers https://t.co/V22smFPl6b
— 1stOncology (@1stOncology) October 20, 2020
@abbvie has announced that the @US_FDA approved a new use of its B-cell lymphoma 2 inhibiting drug #Venclexta in the treatment of AML for some patients. https://t.co/QXcLTf8eoC pic.twitter.com/cwanJDKlsb
— LabPulse (@LabPulse1) October 20, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis | Small Molecules | News Channels – https://t.co/1KdcMjshu3 https://t.co/M9a8MbW3RL #drug #sting
— US Drug News (@USDrugNews) October 20, 2020
In today's News Briefing: AbbVie and Roche’s Venclexta got a new #FDA thumbs up. And ImmunoGen is picking up $40 million in cash from its new partner, Huadong Medicine.https://t.co/BMgst4quQ8
— Endpoints News (@endpts) October 20, 2020
AbbVie and Roche’s Venclexta (venetoclax) Receive the US FDA’s Approval for Acute Myeloid Leukemia https://t.co/RvvC9uD8wj
— PHARMABOX.in (@pharmabox_in) October 19, 2020
@us_FDA grants full approval to venetoclax @abbvie @genentech regimen for certain patients with newly diagnosed acute myeloid leukemia https://t.co/bGB0NCuYPf with comments from Lee Greenberger, PhD @LLSusa pic.twitter.com/WBiPEpuOjg
— HemOnc Today (@HemOncToday) October 19, 2020
The @US_FDA has fully approved @abbvie #Venclexta in acute myeloid leukaemia (AML).
For full article visit: https://t.co/Nf4Uce07io#cancernews #cancerdata #drugapproval— Larvol (@Larvol) October 19, 2020
Read: @abbvie pipeline drug tested as COVID-19 treatment (via @CrainsChicago) https://t.co/qSaGdyDneW
— IMA TODAY (@IMA_Today) October 19, 2020
AbbVie’s Venclexta granted full US approval in AML https://t.co/TGQ5rmtlM9 pic.twitter.com/W9n11lTKM3
— PharmaCrowd (@PharmaCrowd) October 19, 2020
Combination therapies involving @Roche and @AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies https://t.co/09bS6Cx1fY
— pharmaphorum (@pharmaphorum) October 19, 2020
https://twitter.com/hongkong_israel/status/1318093734387613696
.@abbvie submitted applications for U.S. and European approval of its immunology drug Rinvoq for the treatment of patients with moderate to severe atopic dermatitishttps://t.co/BZKlMihLhS $ABBV pic.twitter.com/GInCcSIIs0
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
.@Roche @abbvie's Venclexta granted full US approval for blood cancer indication https://t.co/JPsTWRDfNb $ROG $ABBV pic.twitter.com/lbXANkZlBV
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
Roche-AbbVie's #Venclexta granted full US approval for blood #cancer indication @Roche @abbvie https://t.co/KBOeUVtWyX pic.twitter.com/eHkLHSU1t2
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
AbbVie, Molecular Partners to withdraw EU, Japan applications for #eye therapy @abbvie @MolecularPrtnrshttps://t.co/ynJSf1NVxe pic.twitter.com/Yo6GUuG5L7
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 20, 2020
AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis @Pharmashot @abbvie https://t.co/ZTUHBymu3B pic.twitter.com/Mn7qfv2Guw
— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 20, 2020
AbbVie and Roche’s Venclexta (venetoclax) Receive the US FDA’s Approval for Acute Myeloid Leukemia @Pharmashot @abbvie @Roche https://t.co/sxljcSi8VT pic.twitter.com/9jZa59Z1oa
— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 19, 2020
.@AlexWestchester reports.@NIAIDNews clinical trial examines .@GileadSciences' remdesivir and antibody candidates by .@humanigen, .@Boehringer, and .@abbvie vs. #COVID19. Read more: https://t.co/DXhw6YJyKo pic.twitter.com/gP0SDRAG0n
— Genetic Engineering & Biotechnology News (@GENbio) October 17, 2020
"We are grateful to AbbVie for helping our city obtain the latest and best technology available to combat gun violence," North Chicago Mayor, Rockingham, Jr. said. "ShotSpotter is one more resource our police department will have to make our streets safer https://t.co/w9GRKNLqd4
— Ralph Clark (@ralphaclark) October 17, 2020
NIH initiates ACTIV trial for COVID-19 immune modulators @NIH @JanssenUS @bmsnews @abbvie https://t.co/YrxhDG2Ti4
— The Science Advisory Board (@ScienceBoard) October 16, 2020
"60% reduction in call volumes to service centers was achieved with the help of MyGuide Digital Adoption Platform" – Sandip Patel,@abbvie. Watch and learn how @MyGuideOrg enabled @abbvie to drive seamless employee software-onboarding experiencehttps://t.co/8Q8siHpI9S @karlmehta
— MyGuide by EdCast – Leader in Digital Adoption (@MyGuideOrg) October 16, 2020
The @uspirg contends @abbvie's patent thicket for Humira (adalimumab) will encourage anticompetitive practices by other manufacturers. $ABBV
Read more: https://t.co/MjnS4LjoQH pic.twitter.com/2qDs4AyMpM
— CenterForBiosimilars (@BiosimCenter) October 14, 2020
Amicus brief filed Monday against the maker of Humira. “As the records demonstrate,…@AbbVie engaged in a patent thicket strategy that allowed the company to prolong its Humira monopoly for years beyond what Congress intended.” #RxDrugs https://t.co/5GKzNe9fMz
— U.S. PIRG (@uspirg) October 14, 2020
Bond like $abbv https://t.co/P0bWzE9igu
— WhiteSands Trader (@contango15) October 22, 2020
https://t.co/NlQbz5M03t$TSCO $INTC $MMM @3M @intel $APO $ABBV @abbvie $BNS $SPG
— StocksDiscovery (@StocksDiscovery) October 21, 2020
AbbVie: Now It's Time To Dollar-Cost-Average On This 5.6% Yield (NYSE:ABBV) – https://t.co/NdKV5dWrWK pic.twitter.com/t7AiNomvQI
— Finanz (@FinanzDK) October 20, 2020
4 AbbVie brands land on pharma's top TV spenders list for September https://t.co/Vy1QJyfN6o pic.twitter.com/RUIc94HBsb
— analyst land news (@analystlandnews) October 16, 2020
Thank you to all who participated in @AbbVieUS SF Bay Area Virtual Partnering Day Plenary Session & Panel Discussion! We heard from AbbVie executives about their approach to partnerships and learned about their areas of interest across several therapeutic areas. pic.twitter.com/CPY22EMH3P
— California Life Sciences Association (CLSA) (@CALifeSciences) October 21, 2020
Explore this new technology! @4P_Pharma @abbvie @LillyPad @EvgenPharma @intlstemcell @Merck @Novartis @GSK @pfizer @PharmaLinkInc @TakedaPharma @zimmerbiomet @FlexionInc
— UF Innovate (@UFInnovate) October 20, 2020
Hosted by @CrohnsColitisFn and sponsored by @abbvie, Dr. Bohm and the IU Team will be participating in a virtual spooky #trivianight! We welcome you to participate to learn what will be happening in #IBD in 2020, as well as some costume contest fun! https://t.co/PaTe76iKlK pic.twitter.com/hCHFBbsaga
— Indiana University Gastroenterology (@IUGastro) October 20, 2020
NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr https://t.co/N6R2gcOqEZ
— Joey Sales (@sales_js) October 21, 2020
NIH to test J&J, AbbVie, Bristol Myers Squibb drugs as COVID-19 treatments
The National Institutes of Health plans to test three drugs from Johnson & Johnson, AbbVie and Bristol Myers Squibb as treatments for COVID-19, The Wall Street Journal reported. https://t.co/5ZMXzeCg7f pic.twitter.com/Dkk4bvloVH
— PharmacyWeek (Kevin) (@PharmacyWeek) October 21, 2020
NIH launches trial to uncover if #immunemodulatordrugs from Johnson & Johnson, Bristol Myers Squibb, and Abbvie can restore balance to overactive immune systems in #COVID-19 patients. https://t.co/x861DOUYLb
— pharmanewsintel (@pharmanewsintel) October 20, 2020
NIH to test J&J, AbbVie, Bristol Myers Squibb drugs as COVID-19 treatments https://t.co/7nkaab5BlS pic.twitter.com/5JZV3vRsZG
— Amber Deese Owens (@AmberOwens18) October 19, 2020
NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs | FiercePharma https://t.co/ry1qO7XT7r
— R Mandy Alcuria (@AlcuriaRudolph) October 19, 2020
AbbVie re-ups glaucoma awareness campaign with NFL star Miller https://t.co/oUTvAjxIrc
— NewExpressNews (@NewExpressNews) October 20, 2020
#WeekendReview California AG Joins Coalition Against AbbVie’s Alleged Anticompetitive Practiceshttps://t.co/3MSQWVTrwS
— CPI (@CompPolicyInt) October 18, 2020
CEO of CTYX posted another article on LinkedIn AbbVie to develop and sell China-based I-Mab's cancer drug | Article [AMP] | Reuters https://t.co/SDEsl1OGKs
— Eagle1xOne (@Eagle1xOne) October 21, 2020
Tony Au, general manager of AbbVie China, said, "We are excited about this opportunity and hope to show our commitment to making a remarkable impact on the lives of patients in China." The US firm will participate in the #CIIE for the first time. #WhatTheySay pic.twitter.com/Cd3EpiS5rY
— China International Import Expo (@ciieonline) October 19, 2020
https://twitter.com/fibroidsupport/status/1289126069841399808
Thx to: @abbvie, @accenture, @Aptiv, @Bordbia, @CancilleriaCol, @Entirl, @IDAIRELAND, @InnpulsaCol, @investinbogota, @IrelandiaAvi, @VivaAirCol, @kerryfoodgroup, @MRP_Latam, @Pernod_Ricard, @PlanetPayment, @RubiconCapAdv, @SEPAM_group, @SMBCAVIATION, @smurfitkappa, @PROCOLOMBIACO
— Embajada de Irlanda en Colombia y Panamá (@IrelandColombia) October 20, 2020
#15 position for #AbbVie in the #WorldsBestWorkplaces List by #GreatPlaceToWork!
Congrats! #BestCompany @abbvie @AbbVieItalia #BestCompany2020 #Gptw4all #gptw pic.twitter.com/54Rdw7nKtw— GPTW Italia (@GPTWItalia) October 14, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
A new treatment option in #hepC has just been approved in Japan. Learn more about our exciting news: https://t.co/froz8AgrmO pic.twitter.com/JtQEv0r2gT
— AbbVie (@abbvie) September 27, 2017
#DRG epidemiology report estimates more than 40 million people living with #atopicdermatitis across the United States, Western Europe and Japan @DRGinsights @abbvie #EADV #atopiceczema https://t.co/GzTMBYq1Ve
— DRG Epidemiology (@DRG_Epi) September 14, 2018
Japan awards AbbVie's Skyrizi with first approval, in 4 #psoriasis indications https://t.co/Kfvuazvhrf #pharma pic.twitter.com/safBoeH4EK
— Pharmafocus (@Pharmafocus) March 27, 2019
#Humira's approval in Japan shows that #AbbVie strives to increase its global market share while also increasing the number of indications it can treat with this #biologic. https://t.co/ZZuGEsNTrG
— GlobalData Pharma (@Pharma_GD) March 7, 2019
AbbVie Japan Alters Company Rules for Same-Sex, Common-Law Marriages The Japan arm of AbbVie has changed its company regulations to provide employees who are in same-sex… https://t.co/Xhi9Hp6fVk
— MEDWAVE (@medinfoa2z) August 17, 2020
De momento contento de llevar $ABBV
AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come $ABBV https://t.co/KRaIiZzu7T
— Josue (@goldesenyo) April 12, 2019
Another great option for people with #psoriasis. #AbbVie gets the first global regulatory approval of #SKYRIZI in Japan https://t.co/Jn6OgT2EbF via @AsiaBioSpectrum
— International Psoriasis Council (@IpcPs) March 27, 2019
$ABBV – AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come https://t.co/6bTcWFL6WE
— Jeffrey Weber (@jjjinvesting) April 11, 2019
Hats off to all the American companies that are pitching in to help Japan recover from Typhoon Hagibis. Among them are @united, @Merck, @abbvie, and @KEEN. Oregon Governor Brown and I met with representatives of @KEEN_Japan to extend our appreciation. pic.twitter.com/v2ieUTdmvC
— ジョセフ・M・ヤング 駐日米国臨時代理大使 (@USAmbJapan) November 21, 2019
Galapagos: Chasing AbbVie, Gilead files for approval of filgotinib in Japan $GLPGhttps://t.co/4xtyxlLMWR
— Lama Daila (@Lama_Daila) October 8, 2019
#AbbVie receives priority review for new 8-week DAA in Japan https://t.co/R3Lmmj3zG8 #HCV
— Healio Hepatology (@HealioHep) March 15, 2017
AbbVie's Viekirax approved as #HCV treatment in Japan: http://t.co/LwtqdFmT8s @AbbVie RT pic.twitter.com/KPV1ifdAwh
— European Pharmaceutical Review (@PharmaReview) October 1, 2015
With hep C approval app, AbbVie eyes franchise growth in Japan http://t.co/doMYaxyJlM $ABBV #pharma via @FiercePharmAsia
— FiercePharma (@FiercePharma) February 12, 2015
https://twitter.com/galamericas/status/1317122908829908992
AbbVie, Amgen and Takeda team up for joint COVID-19 trial – PMLiVE https://t.co/l47HbqyU9v
— Pharmaceutical Market Europe (@PMLiVEcom) August 5, 2020
AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study https://t.co/IzrYEnmjmV
— PhRMA (@PhRMA) August 4, 2020
AbbVie, Amgen and Takeda jointly study impact of anti-inflammatory drugs in COVID-19 treatment @ExpPharma https://t.co/jWG55UmxUE
— IJPSonline (@IndianJPharmSci) August 4, 2020
AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study https://t.co/1IlYuJzeVe
— iBIO (@IllinoisBiotech) August 4, 2020
Rival drugmakers launch joint trial of drugs for #COVID19 https://t.co/LcRNln9jaK @gulf_news #coronavirus @AbbVie @Amgen @Takeda
— Gulf News Business (@GulfNewsBiz) August 3, 2020
AbbVie, Amgen, Takeda launch joint trial of potential COVID-19 drugs https://t.co/J2kmg2aHtE
— FirstWord Pharma (@fwpharma) August 3, 2020
Abbvie, Amgen and Takeda begin patient trial for Coronavirus vaccine https://t.co/j43q68CeRs
— PageOne.ng (@PageOne_NG) August 3, 2020
AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments https://t.co/d8RdZY3U1g
— MarketsTicker (@MarketsTicker) August 3, 2020
AbbVie, Amgen and Takeda begin testing drugs as COVID-19 treatments https://t.co/3V3KhrwqAT
— MarketWatch (@MarketWatch) August 3, 2020
Rival drugmakers AbbVie Inc , Amgen Inc and Takeda Pharmaceuticals Inc. said they have begun treating patients in a trial. | @reuters https://t.co/5EJHUF7fmQ
— Inquirer (@inquirerdotnet) August 3, 2020
#covid19 cases seem to be reducing in Italy & China. Plus masses of big biotech, pharma & vaccine companies are pouring $bns into finding a cure, eg Gilead, Pfizer, GSK, Takeda, AbbVie, Moderna.
I appreciate no-one has the answer yet, but I suspect they'll get before the y/e pic.twitter.com/haEYH2cUOZ
— PMH Capital (@CapitalPmh) March 4, 2020
Takeda's Entyvio outperforms AbbVie's Humira in moderate-to-severe #UlcerativeColitis https://t.co/RBvxGE4VEN #pharma pic.twitter.com/8duoTU0NH1
— Pharmafocus (@Pharmafocus) September 27, 2019
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in: Novartis, Merck, GlaxoSmithKline (GSK), Gilead, Bayer, AstraZeneca, AbbVie and Takeda offered their opinions on recent FDA draft guidance on potential drug-drug interactions… https://t.co/usSBncXDwt
— cafepharma (@cafepharma) July 27, 2018
Great opportunities for @ucdscience and engineering students/grads:
☑️NIBRT Careers in Biopharma event in UCD Campus on 13 April
☑️Companies attending include J&J, BMS, Sanofi, Allergan, Amgen, Grifols, Takeda, AbbVie
☑️Further details on https://t.co/zpHbKRFHvq. https://t.co/0N3eoSrKZK
— UCD Chemistry (@ucdchemistry) March 20, 2019
On Saturday, IPhO held its 4th annual Pharma Fair! Student pharmacists from over the country came to network with reps from pharmaceutical companies such as Takeda, AbbVie, & more.
Our students are making key connections that will put them on the path to success! pic.twitter.com/6sGk11Cz4e
— UIC Pharmacy (@UICPharm) October 28, 2019
Takeda buy Shire
BMS buy CellgeneAnd now … Abbvie buy Allergan
All are BIG players with significant stakes in current / future therapies for #IBD
It will be very interesting to watch this play out. Hopefully it means more R&D investment that translates to the clinic. pic.twitter.com/EpoUnt9yXD
— Charlie Lees (@charlie_lees) June 25, 2019
MSBE, BT and GCB students check out the Careers in Biopharma event in NIBRT on April 13th 2019. Companies attending include J&J, BMS, Sanofi, Allergan, Amgen, Grifols, Takeda, AbbVie.
Further details on https://t.co/pqVYveVS0o
— Brian Freeland (@BFreelandDCU) March 19, 2019
Big Pharma’s first female CEO is engineering a radical shake-up, taking a different path than Bristol-Myers Squibb, Takeda Pharmaceutical, and AbbVie, which are reinventing themselves with megadeals.
Read more at: https://t.co/kirykEPAe0
— menaka doshi (@menakadoshi) July 18, 2019
8 New drug structures revealed at #ACSOrlando….see them here !
Companies include: Amgen, Abbvie, Novartis, Takeda, Pfizerhttps://t.co/ZE68xbb5r7 pic.twitter.com/tYbPMJ45Gj— Organic Process Research & Development (@OPRD_ACS) April 5, 2019
Endometriosis Treatment Market New Opportunities For Growth And Profitable Business Development 2026 Evaluated By Global Players Meditrina Pharmaceuticals, Abbvie, PfizerInc, Takeda Pharmaceutica, and Neurocrine Biosciences Inc https://t.co/HhbepHFlxV via @openPR
— Raj Bisen (@Rajbisen210) February 26, 2019
https://twitter.com/AxiomaGroupInc/status/1301584540507439109
J&J may be a little behind with the COVID-19 vaccine, but they may still have an advantage.https://t.co/T4ubxOcCdg#competitiveadvantage #vaccine #strategy #jnj #pfizer #allergan #takeda #abbvie #amgen #moderna #covid19 #pharma #biopharmaceuticals #biopharma #coranavirus #lead pic.twitter.com/OiE3GZXTcX
— Axioma Group, Inc. // Strategy + Innovation (@AxiomaGroupInc) August 12, 2020
https://twitter.com/AxiomaGroupInc/status/1291191015701872643
Prostate Cancer Diagnosis and Treatment Market Supply-Demand, Industry Research and End User Analysis, Outlook 2026 | COVID19 Impact Analysis | Key Players: Abbott Laboratories, AbbVie, Active Biotech, Amgen, Astellas Pharma, etc. https://t.co/SReC9xp1Jy
— mednetnews (@mednetnews) October 2, 2020
https://twitter.com/KNOW_AML/status/1252583034622263297
Cancer Therapeutics Market Estimated to Reach at $178,863 million by 2023 – F. Hoffmann-La Roche,Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Celgene, Astellas, Pfizer, Novartis, Merck, Eli Lilly – Downey Magazine https://t.co/0lBoYnbg4h
— Cross the Creek (@creek_cross) December 26, 2019
Research Segment of Endometriosis Drugs Market (2020 – 2029) | AbbVie, Astellas Pharma, AstraZenecahttps://t.co/Zz5keb7j2s#news #pharma #pharmiweb
— Pharma News (@pharminews) December 23, 2019
Global Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and Astellas Pharma Inc. | Technavio https://t.co/MScX9lj3gm
— Pharmacutical Daily (@PharmacDaily) November 5, 2019
Don't be left out of the celebrations – Entries from @abbvie @Bayer @astellas @Novartis @JanssenUS already, so don't miss out on your chance to be part of the #efpawards Download your entry pack here https://t.co/Trk5qhLrNR pic.twitter.com/3ibsDJAd67
— Reuters Events Pharma (@RE_Pharma) June 25, 2019
Biopharmaceuticals Market Outlook to 2025 :Inflammatory , Infectious Diseases, Autoimmune Disorders, Metabolic Disorders,| With Top Key Players AbbVie, Amgen Astellas BioPharma, Johnson & Johnson, No https://t.co/EexNJ7Z3l2
— PressRelease.cc (@PressRelease_cc) February 19, 2019
Global Prostate Cancer Drugs Market 2018 Top Intelligence:- AbbVie, Astellas Pharma, Astra Zeneca, Johnson & Johnson, Sanofi https://t.co/OaKEt1Qsin
— Tammy V Wyatt (@tammyvwyatt) January 21, 2019
Hear from Abbvie, Novant Haelth, Astellas, and more at the Strategic Internal Comms for Health Care in April – https://t.co/NUsASWbuVz
— ALI Conferences (@aliconferences) March 16, 2017
NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs https://t.co/mmnoWBwa4Y #NIH #JohnsonAndJohnson #BristolMyersSquibb #AbbVie #AntiInflammatoryDrugs https://t.co/vE5QbcsRYJ
— Haybury (@Hayburysearch) October 20, 2020
Bipolar disorder therapeutics market: Top players are Novartis AG, Allergan, Otsuka Holdings, AbbVie etc. – Credence Turbine https://t.co/r9Q5pnDX42
— Schizocidal (@schizocidal) July 10, 2020
Autism Disorder and Treatment Market Growth 2026: Including Key Players Otsuka, AstraZeneca, Pfizer, AbbVie, Johnson & Johnson Services, GlaxoSmithKline https://t.co/8GAlL0MDgR
— Market Research Nest (@marketrnest) April 6, 2020
The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd#sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn
— Reuters Events Pharma (@RE_Pharma) August 14, 2019
Japan Oncology Drugs Market Opportunities with Leading Players: Daiichi Sankyo Co Ltd, AstraZeneca plc, AbbVie Inc., Celgene Corporation https://t.co/cTWBLWxisp
— Aditi Desai (@Aditi04986849) November 28, 2019
New post (Humira Market Report Expected Massive Growth By 2020-2025 | AbbVie, Eisai, Torrent Pharmaceuticals) has been published on https://t.co/fdzRB6KRVD – https://t.co/ioErwtJuF5 pic.twitter.com/enQI4mWqu9
— Top News Corner (@topnewscorner) September 15, 2020
Humira Market (2020-2029) : Ranking down the Industry System, Geography and Business sections of the major players AbbVie, Eisai, Cadila Healthcarehttps://t.co/2fA5xvIEqd#news #pharma #pharmiweb
— Pharma News (@pharminews) January 28, 2020
Strategic Overview of the Global Humira Market Exploring the Present and Future State -AbbVie, Eisai And Cadila Healthcare – https://t.co/QnvrzJt4eF #pharma #news
— Pharma News (@pharminews) July 15, 2019
AbbVie and Eisai Announce Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa | News Release：2019 | Eisai Co., Ltd. https://t.co/HE4j8WWYlh
— Krishan Maggon (@kkmaggon) February 22, 2019
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA https://t.co/2jOFyHj7qY pic.twitter.com/ZmYb9G36JO
— Haleplushearty.org (@haleplushearty) February 21, 2019
AbbVie and Eisai obtain additional approval for Humira https://t.co/hQFi3njXEo via @NewsNowUK
— francis loos (@claoseun) April 3, 2018
U.S.A. アメリカ Vol.116（California カリフォルニア州 Vol.2: pharmaceutical corporations 製薬会社）
All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
California Vol.25 (corporations: Amgen)
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Since 2011, Amgen has doubled its global presence and, with the addition of Amgen K.K., that now includes Japan. In 2019 alone, we invested more than $4 billion in global research & development to serve more patients. Press release: https://t.co/uBT5FT4fnw 2/2 pic.twitter.com/wstcLnvnnz
— Amgen (@Amgen) April 1, 2020
We’re pleased to introduce Amgen K.K., a wholly-owned affiliate in Japan which will enable Amgen to build a strong presence in the country moving forward. Amgen K.K. will focus on bringing our full global pipeline to Japanese patients. Press release: https://t.co/uBT5FT4fnw 1/2 pic.twitter.com/fkqXj6g6Tm
— Amgen (@Amgen) April 1, 2020
#Amgen’s New #Osteoporosis Treatment Receives First Worldwide Approval in Japan https://t.co/JooD4GUxgK @UCB_News
— Amgen (@Amgen) January 8, 2019
#ICYMI, #Amgen’s medicine for R/R ALL has received marketing authorization in Japan. Learn more: https://t.co/UMrQByPqtD
— Amgen (@Amgen) September 26, 2018
#Amgen receives approval for our R/R ALL medicine in Japan. Learn more: https://t.co/UMrQByPqtD
— Amgen (@Amgen) September 25, 2018
Applications for the #AmgenScholars Program in Europe, Japan & the U.S. are open now: https://t.co/uVtH11AW1w pic.twitter.com/rt3JekGqix
— Amgen (@Amgen) December 13, 2017
The #AmgenScholars Japan Symposium was a global gathering of passionate young #scientists. Learn more: https://t.co/CvuLhtGpQF
— Amgen (@Amgen) January 10, 2017
#Amgen & @UCB_news announce submission of marketing application in Japan for osteoporosis treatment https://t.co/Z27LnrD17x
— Amgen (@Amgen) December 20, 2016
#Amgen submits marketing application in Japan http://t.co/DSa8puB2Ms
— Amgen (@Amgen) March 20, 2015
#Amgen presents new detailed cholesterol data from Japan study at #ACC15 http://t.co/A8Crv951Em
— Amgen (@Amgen) March 14, 2015
Japan’s #biosimilar guidelines aim toward #quality, #safety and #efficacy. Full article: http://t.co/xzDMFOgozN via @GaBIOnline_
— Amgen (@Amgen) September 27, 2013
As the Japan #AmgenScholars Program enters its fifth year, Steve Sugino, Vice President of @Amgen, caught up with its Directors, Dr. Ichiro Sakuma and Dr. Fuyuki Ishikawa about their experience with the program. https://t.co/2opFJZxRUb
— Amgen Foundation (@AmgenFoundation) April 10, 2019
@Amgen establishes a wholly-owned affiliate in Japan by announcing the completion of 49% share buyout in a 7-year-old joint venture with Astellas Pharma Inc.#Japan #Healthcare #GeneOnlinehttps://t.co/rfMMQHKd9e
— GeneOnline (@GeneOnlineNews) April 1, 2020
#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC
Read: https://t.co/Ra1FDwHAXE@Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr
— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019
What are the key challenges for #osteoporosis patients in #Japan and how are these affecting their daily lives? Our persona portrait explores the issue. #bonehealthAsia https://t.co/6I7R6gsnr3 (Commissioned By @Amgen) pic.twitter.com/XSzyeHQBpH
— The Economist Intelligence Unit (@TheEIU) March 28, 2019
In Japan, #cardiovascular diseases (CVDs) levy US$24.3bn in direct and indirect costs on individuals, their households and the public finances. What can be done to reduce CVDs costs? Download report> https://t.co/GvIrb2yynd (Via @Amgen) #HearthealthAsia pic.twitter.com/b0syBOLu9W
— The Economist Intelligence Unit (@TheEIU) December 21, 2018
Amgen and UCB's Evenity approved in Japan for #osteoporosis https://t.co/GvzSmOIQv5 #pharma @Amgen @ucb_news pic.twitter.com/gcs0QJ4SJi
— Pharmafocus (@Pharmafocus) January 9, 2019
BLINCYTO® (Blinatumomab) Approved in Japan for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia @Amgen https://t.co/TxsNrf7oZ1
— Hematopoiesis News (@Hema_News) September 28, 2018
Japan to cut drug prices, @bmsinfo @OnoPharmaOpdivo (nivolumab) & @Amgen Repatha (evolocumab) into the spotlight https://t.co/3xzxFn3muY
— ilS (@ilsintelligence) September 19, 2016
@Amgen's #Repatha wins first PCSK9 OK in #Japan https://t.co/EeEEqDTq40 @FiercePharma #hypercholesterolemia #cholesterol #cardiovascular
— Plexus Ventures (@PlexusVentures) January 25, 2016
@Amgen signs autoimmune pact with Japan's Teijin – Read more via @PharmaTimes here: http://t.co/OlktgphSz9 #autoimmune #Japan #pharma
— Plexus Ventures (@PlexusVentures) August 1, 2013
#Amgen announces approval of Repatha® (evolocumab) in Japan https://t.co/uOn5L1sab3
— Amgen (@Amgen) January 22, 2016
#Amgen and Astellas Announce Japan Alliance http://t.co/oRgJwzycLz
— Amgen (@Amgen) May 29, 2013
Amgen Repurchases Astellas’ Stakes in Amgen Astellas JV to Strengthen its Footprints in Japan @Amgen @AstellasUS https://t.co/9RLS4NdZg2 pic.twitter.com/5eHR6tMorO
— PharmaShots – Incisive news in 3 shots (@Pharmashot) April 1, 2020
@Amgen establishes a wholly-owned affiliate in Japan by announcing the completion of 49% share buyout in a 7-year-old joint venture with Astellas Pharma Inc.#Japan #Healthcare #GeneOnlinehttps://t.co/rfMMQHKd9e
— GeneOnline (@GeneOnlineNews) April 1, 2020
Amgen & Astellas Enter Into Japan Alliance http://t.co/345v46RfBp @amgen @AstellasUS
— Asian Scientist Magazine (@asianscientist) June 7, 2013
#Amgen and @DaiichiSankyoJP announce agreement to commercialize #biosimilars in Japan. https://t.co/bVDl6FJaet
— Amgen (@Amgen) July 14, 2016
#collaboration between @Amgen and @EUdaiichisankyo to #commercialize nine #biosimilars in #Japan.
For more: https://t.co/R2fyWqM00i— Roots Analysis (@RootsAnalysis) July 18, 2016
@Amgen & @DaiichiSankyo announce agreement to commercialize #biosimilars in #Japan https://t.co/D3xmqmRiJo @WorldPharmaNews #biosim #pharma
— Plexus Ventures (@PlexusVentures) July 14, 2016
.@Amgen agrees deal to commercialise biosimilars in Japan with @EUdaiichisankyo https://t.co/O7cdaYN3Ml
— Pharmafocus (@Pharmafocus) July 14, 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan https://t.co/KsanOqAcmi [h/t @Amgen]
— Endpoints News (@endpts) July 14, 2016
.@Amgen partners with @DaiichiSankyoJP to market biosimilars in Japan https://t.co/fieuGDAidm via @biopharmadive pic.twitter.com/hsWno7fsfd
— NewYork Pharma Forum (@NYPharmaForum) July 23, 2016
.@Amgen partners with @DaiichiSankyoJP to market biosimilars in Japan https://t.co/UpKRfQvYGV via @biopharmadive pic.twitter.com/6H9mg6Ou5y
— NewYork Pharma Forum (@NYPharmaForum) July 22, 2016
AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study | @AbbVieUS @Amgen @TakedaOncology @WHO #cambridge #massachusetts #thousandoaks #california #covid19 #biotech https://t.co/HAJfTVcTOR
— Pharm2Market (@pharm2market) August 6, 2020
Rival drugmakers launch joint trial of drugs for #COVID19 https://t.co/LcRNln9jaK @gulf_news #coronavirus @AbbVie @Amgen @Takeda
— Gulf News Business (@GulfNewsBiz) August 3, 2020
Our heads of R&D, Takeda's Andy Plump and @Amgen's David Reese, published a @statnews opinion article about the efforts of the COVID R&D Alliance and the power of adaptive trials. Learn how a global network can accelerate the fight against #COVID19 https://t.co/x5gYQT8nVj pic.twitter.com/lXs0YOkkVK
— Takeda (@TakedaPharma) July 23, 2020
Affymax banks $50M milestone on ESA drug approval http://t.co/T5PeWE5y $AFFY $AMGN @Takeda @Amgen
— FierceBiotech (@FierceBiotech) April 10, 2012
#Peptide_Based_Cancer_Therapeutics Market Size Worth $17.18 Billion By 2027
Read More : https://t.co/k5GadYh4D3
major market participants :@AstraZeneca @Allergan @Pfizer @Takeda @Amgen,@JNJNews#peptidetherapeutics #healthcare pic.twitter.com/8LF46fwnPm
— karishma mulani (@karishmamulani5) July 28, 2020
.@TakedaPharma to return molecules/ products for Japan to @Amgen https://t.co/14hGlLgKu6
— Pharmafocus (@Pharmafocus) June 27, 2016
参考．上記linkに無いもの
“The world now recognizes that we need innovation to get out from under the crush of this pandemic.”
Amgen CEO Bob Bradway spoke with @FT's @HannahKuchler about navigating #COVID19 now and preparing for a post-COVID world. #FTUSPharma $AMGN
— Amgen (@Amgen) October 6, 2020
If you’re a provider, visit our updated #COVID19 & cardiovascular resource page which also includes a link to important resources in the @HFSA COVID-19 resource hub to learn more.
Details in the link below.
— Amgen (@Amgen) October 1, 2020
Amgen's Michelle Carillo from our advocacy relations team will join for this discussion. Registration details in link below. #COVID19 https://t.co/wLqtf8dr8A
— Amgen (@Amgen) September 29, 2020
Moderated by MassBio CEO @BobCoughlin, Michelle Carrillo @Amgen, Dr. Meghan Mooradian @MassGeneralNews & Kirsten Sloan @ACSCAN join us now for a discussion on how #COVID19 has impacted cancer care & the path to diagnosis & treatment. Thank you, @Amgen for sponsoring this event! pic.twitter.com/mG5Lb9Hd8f
— MassBio (@MassBio) October 1, 2020
Dr. Steven Galson of @Amgen discussing #COVID19 and the promise of genetic sequencing. A great conversation on how science is meeting this critical moment for our world. #CALeg pic.twitter.com/rn7kDoqWap
— California Biotech (@CABiotech) May 28, 2020
.@PhRMA companies and CMTA members @LillyPad, @TakedaPharma, @pfizer, @JNJInnovation, @Amgen, @Novartis part of coordinated intl. research response for #COVID19 treatments and vaccines. #MakingCA #ProtectingUS https://t.co/K81hC2aHPe
— California Manufacturers & Technology Assn. (@cmta) April 21, 2020
Wonderful news from CLSA members @Amgen and @LillyPad!
The spirit of life sciences collaboration embodies our ability to defeat this pandemic! #innovation > #COVID19 https://t.co/NnfbMCq62H
— California Life Sciences Association (CLSA) (@CALifeSciences) September 17, 2020
In the fight against the pandemic, @LillyPad announced a partnership with @Amgen to #manufacture a new #COVID19 treatment! #CreatorsRespond https://t.co/ihMQVEWabZ
— Friends of Manufacturing (@FriendsofMFG) September 17, 2020
Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies. @WorldPharmaNews @LillyPad @Amgen #COVID19 #antibodies #LYCoV555 #lifesciences #pharma https://t.co/h2TiFilMDl pic.twitter.com/bUbAsek5xs
— Greybridge (@GreybridgeRoles) September 22, 2020
With rising numbers of #diabetic and #chronicdisease #patients, the #wearable #injectors market is growing for ease of #drugadministration. (https://t.co/dNV34tAMEh)
.
.
.#injection #syringe #drugdelivery #medicine #Amgen #BD #Insulet #Medtronic #COVID19 #TBRC #GlobalMarketModel pic.twitter.com/jExYhkjBf7— TBRC (@tbrc_info) September 22, 2020
Amgen adapts to pandemic with #Prolia home infusion; #Otezla as COVID-19 therapy @Amgen #covid19 #earnings@MichaelHGibney reports https://t.co/lsTmjgdaDz pic.twitter.com/psknF2KIok
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 29, 2020
Discover what it's like to be an outbreak response team member in Amgen #BiotechExperience's new virtual curriculum module that explores the #COVID19 pandemic, Responding to a Mystery Illness.
Read all about it: https://t.co/kecQFvdMA4 pic.twitter.com/TqquQDmqdT— ABE Program Office (@ABEProgOffice) April 27, 2020
Working with @AdaptiveBiotech, @Amgen is working on a drug to treat #COVID19. #CreatorsRespond https://t.co/BKYN0PgIk6
— The NAM (@ShopFloorNAM) April 3, 2020
First Patients Registered in I-SPY COVID Trial https://t.co/4wzf17dWb6 via @GMP news #AbbVie #Amgen #ClinicalTrials #Covid19 #Takeda #GMPNews
— GMPnews.Net (@GMPnewsNet) August 4, 2020
Tune in as @American_Heart CEO @NancyatHeart and @Amgen CEO Bob Bradway discuss #COVID19 rapid response efforts, especially for heart disease and stroke patients who are at higher risk & rightfully concerned. https://t.co/rAOt9UJFD4
— American Heart News (@HeartNews) May 19, 2020
Thank you @Amgen Canada for your donations, supplies, and expertise to our Canadian communities to help fight against #COVID19. #CanadaResilient Learn more > https://t.co/70V9BlXh29 pic.twitter.com/Mo34pp6FPg
— Mississauga Business (@MississaugaEDO) May 6, 2020
At shareholder meetings this spring investors asked #BigPharma to commit to freeze prices on key drugs in light of the #COVID19 pandemic. Tomorrow the industry is set to again raise prices. CEO Bradway of @Amgen – will you commit? https://t.co/Aratl9g4iU
— ICCR (@ICCRonline) June 30, 2020
#NasdaqListed @Amgen marks a major milestone with a note of gratitude to #healthcare workers.
How they're stepping up to address the #COVID19 pandemic: https://t.co/PBb1vBMhAd https://t.co/0pWytEJcHp pic.twitter.com/R9aolBQRET
— Nasdaq (@Nasdaq) April 8, 2020
Boehringer Ingelheim-backed COVID researchers identify new antibodies to fight the virus | @boehringerus @UniCologneNY @DZIF_ @lillypad @Regeneron @Amgen @AstraZeneca #immunesystem #covid19 #biotech #research https://t.co/T8Y9zaIVX0
— Pharm2Market (@pharm2market) July 11, 2020
U.S.A. アメリカ Vol.113（Massachusetts マサチューセッツ州 Vol.2: pharmaceutical corporations 製薬会社）
All the below links and tweets are in English.
取り急ぎ以下貼っておきます。
Massachusetts Vol.19 (corporations: Moderna)
Massachusetts Vol.20 (corporations: Biogen)
ツイッター検索で 上記2製薬会社各社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273): https://t.co/jpsGTOv9BQ pic.twitter.com/fo0XC7pCXo
— Moderna (@moderna_tx) August 28, 2020
.@TakedaPharma sets up deal to distribute @moderna_tx’s #COVID19 #vaccine in Japan: https://t.co/h7QCDUi89A
—#biomanufacturing #bio #biopharma #pharmaceutical #pharma #healthcare #manufacturing #coronavirus #pandemic pic.twitter.com/sTJPWEkjXv
— American Biomanufacturing (@BioMfg) September 2, 2020
Moderna to potentially supply Japan with 40M doses of COVID-19 vaccine @moderna_tx https://t.co/pRlHBWh3uk
— The Science Advisory Board (@ScienceBoard) August 28, 2020
American biotech company @moderna_tx has confirmed it is in discussions with #Japan's government over the potential purchase of 40 million or more doses of COVID-19 #vaccine.https://t.co/XKNJ7uC317
— The Jerusalem Post (@Jerusalem_Post) August 28, 2020
The #US-based biotech company #Moderna (@moderna_tx) has confirmed talks to supply 40 million doses of its potential #COVID19vaccine to #Japan. pic.twitter.com/qYDWaNTdQm
— IANS Tweets (@ians_india) August 30, 2020
“The [@moderna_tx] #vaccine candidate… would be distributed in Japan by @TakedaPharma, beginning in the first half of 2021… #Japan has already signed agreements with other drugmakers such as @Pfizer & @AstraZeneca, as well as local ones like #Shionogi & Co…” #COVID19 https://t.co/awQJyQhnpN
— Mark Warner (@MAAWLAW) August 28, 2020
COVID-19 Vaccine Pipeline https://t.co/z9QJ2v4RBj via @kyodo_english #WHO @moderna_tx #NIAID @InovioPharma @BioNTech_Group #ClinicalResearch "Even if overseas vaccines have success and received special regulatory approval, the supply in Japan will be limited"
— ClinicalBid (@ClinicalBid) June 30, 2020
We are proud to announce that we are working with @biogen Japan LTD. to create a system to respond faster and more accurately to questions from patients, the media, physicians & other constituents at its Medical Information Department (MID).
Read more: https://t.co/7R11MuIgCa
— Lexalytics (@Lexalytics) September 18, 2019
Program two "Gene Lab" @miraikan in Japan- Students worked on experiments w/electrophoresis and recombining DNA! #STEM #HandsOnScience pic.twitter.com/9AZ3JUGqgg
— Biogen (@biogen) March 21, 2017
Our Rare Disease treatment is now approved across the globe in Australia, Brazil, Canada, EU, Japan, Switzerland and the US #ProudMoments2017 pic.twitter.com/5lyBePTfYs
— Biogen (@biogen) December 22, 2017
Heading to Japan to be part of #WCN17 focused on the future of #neurology. Follow @Biogen for the latest! pic.twitter.com/A4yU2kFTci
— Biogen MS (@biogenms) September 15, 2017
Exciting moments w/ students @miraikan in Japan during "Gene Lab" hands-on experiment events – “E-coli glowing in the dark”! #STEM #Science pic.twitter.com/ak7wee6o7L
— Biogen (@biogen) March 13, 2017
Great to have @BiotechTour ambassadors & @miraikan representatives at our Japan office @sciencecenters #WBT2015 #STEM pic.twitter.com/MwPNSmJ9TH
— Biogen (@biogen) August 3, 2015
.@BiotechTour 2015 continues with it's next stop in Tokyo, Japan @miraikan (August 8 ceremony) http://t.co/12YAJjg4zn #WBT2015 #STEM
— Biogen (@biogen) July 28, 2015
An amazing day at @miraikan WBT festival! Thank you @biogen and @ScienceCenters for your support in Japan #WBT2015 pic.twitter.com/mqNeOMi9nU
— WorldBiotechTour (@BiotechTour) August 8, 2015
This year we celebrated our 40th anniversary with events in the U.S., Japan and Switzerland. Almost 2K employees, experts, physicians, patients and reporters were able to join us to reflect on the important moments that shaped our past, and our bright future. #ProudMoments2018 pic.twitter.com/iTnlHrhFZz
— Biogen (@biogen) December 11, 2018
#DRG epidemiology report estimates more than 15,000 people diagnosed with #SMA across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #spinalmuscularatrophy #RareDiseaseDay @biogen https://t.co/PguIonrUSW
— DRG Epidemiology (@DRG_Epi) March 5, 2020
#DRG epidemiology report estimates more than 15,000 people diagnosed with #SMA across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #spinalmuscularatrophy #EAN2019 @biogen https://t.co/vNfzsxdEAd
— DRG Epidemiology (@DRG_Epi) July 3, 2019
#DRG epidemiology report estimates more than 35,000 diagnosed prevalent cases of #amyotrophiclateralsclerosis across the United States, Western Europe and Japan. Detailed report available now @DRGinsignts #ALS #WorldALSDay @biogen https://t.co/pE5tSpaPpw
— DRG Epidemiology (@DRG_Epi) June 24, 2019
More than 10 million people are living with #Alzheimersdisease across the United States, Western Europe and Japan. Stay tuned for more updates on #DRG global epidemiology data @DRGinsights @biogen #AlzheimersAwarenessMonth https://t.co/MmNdFkPrzQ
— DRG Epidemiology (@DRG_Epi) November 6, 2018
How about a deal with @SangamoTx to better exploit protein homeostasis? Hematology is unpartnered @ScienceAtBMS @bmsnews @JoeSzustakowski.
Partners include @sanofi @NovartisScience @pfizer #takeda @GileadSciences @KitePharma @biogen$SGMO $BMY $PFE $NVS $SNY $GILD $BIIB https://t.co/tJzQPwFTgB— biotech 2050 (@Biotech2050) July 30, 2020
Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx
— Open Targets (@targetvalidate) June 21, 2019
Takeda joins Open Targets drug discovery initiative. @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/XOHP4TPSpX pic.twitter.com/qPW97LuHPW
— Sanger Institute (@sangerinstitute) December 5, 2017
The Dementia Discovery Fund first launched in 2015 with $100 million in capital from a range of Big Pharma companies, the U.K. government and the non-profit Alzheimer's Research UK @Biogen @GSK @Johnson&Johnson @Lilly @Pfizer @Takeda @ARUK @DHSCgovukhttps://t.co/tdtENajGGx
— The Dementia Discovery Fund (@TheDDFund) August 9, 2018
.@TheDDFund $350M raise included $60M from @AARP as part of its #DisruptDementia initiative; fund spearheaded by #biopharma group that included @biogen @LillyPad @GSK @JNJNews Otsuka @pfizer @TakedaPharma
— BioWorld (@BioWorld) June 25, 2018
Former @biogen R&D guy @michael_gilman has a new biotech today, Obsidian, founded in 2015 by Atlas. A $50M Series A round was led by GV, the venture arm of Alphabet, & includes Atlas and the venture arms of Takeda and Amgen. by @BosBizMax https://t.co/HPYNg8DZaA
— Don Seiffert (@BosBizDon) December 6, 2017
#Biotech Industry in #Boston Reacts to #Coronavirus, Implements Containment Measures | @Biogen execs instructed to quarantine and isolate themselves from loved ones, and @Takeda implementing work-from-home for workforce | #COVID19 #SARSCoV2 #2019nCoV https://t.co/80oCHVVDbN
— Patrick Henry Warren (@phwarren360) March 9, 2020
https://twitter.com/bmd_congress/status/1165337983094067201
Great news that Takeda has joined the Open Targets drug discovery initiative. More here: https://t.co/XOHP4TPSpX @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/8SFnDO41B2
— Sanger Institute (@sangerinstitute) December 5, 2017
ADI would like to thank our supporters whose generosity enabled us to run yet another successful #WorldAlzMonth campaign; in particular, Acadia Pharmaceuticals, @biogen, @JanssenUK, @Lundbeck, Otsuka & @Roche. Thank you! pic.twitter.com/Pej52CpUhz
— ADI (@AlzDisInt) October 2, 2020
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus | @Roche @Eisaius @Biogen @Quest @HMHNewJersey @hallnursing #Nutley #NewJersey #Cambridge #Massachusetts #Biotech #neurodegenerative #diabetes #cancer #alzheimer #parkinson https://t.co/ce0EkdSrJF
— Aspen Biosciences (@aspenbio) August 12, 2020
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus | @Roche @Eisaius @Biogen @Quest @HMHNewJersey @hallnursing #Nutley #NewJersey #Cambridge #Massachusetts #Biotech #neurodegenerative #diabetes #cancer #alzheimer #parkinson https://t.co/IkXPDuB59M
— Pharm2Market (@pharm2market) August 12, 2020
Biogen and Eisai Complete the Submission of BLA to the US FDA for Aducanumab to Treat Alzheimer’s Disease @biogen @EisaiUS https://t.co/A9YmZfSPUW pic.twitter.com/rGx3wODNiz
— PharmaShots – Incisive news in 3 shots (@Pharmashot) July 9, 2020
Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer’s Disease @biogen https://t.co/nSOsjsoRZo pic.twitter.com/WrFji1EsGZ
— PharmaShots – Incisive news in 3 shots (@Pharmashot) March 22, 2019
Biogen, Eisai seek priority US #FDA review of #Alzheimer's drug @biogen https://t.co/1w1SRBawS1 pic.twitter.com/1rd7XK4AdE
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 9, 2020
Global #Alzheimers #Drugs Market 2019 — Eisai Pharmaceuticals, @Allergan, Amgen, @Biogen https://t.co/g6tC6YC5KB
— Marketstudy (@Marketstudy1) October 25, 2019
Biogen, Eisai revive plans for Alzheimer’s drug #Alzheimers @biogen https://t.co/0ChzgxABqB
— Pharmacy Business (@PharmacyBiz) October 24, 2019
This is incredibly disappointing news, but just another reason we have to keep up the fight. Alzheimer's is relentless, so are we. #endalz @biogen @eisai
Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment https://t.co/skleIwPUcw
— Carey Ann Comeau (@careyanncomeau) September 17, 2019
Due to unfavorable risk-benefit, @Eisai_SDGs & @biogen discontinue Ph3 #clinicaltrials of #elenbecestat vs early #Alzheimers#BACE inhibitor was studied in patients w/ mild #cognitive impairment or mild AD + #amyloid pathologyhttps://t.co/MPKXpGK141#neuroscience #dementia pic.twitter.com/ik4Dc4JCpH
— DDNews Online (@DDNewsOnline) September 13, 2019
Eisai kickstarting alternate Alzheimers’ drug after failure of Aducanumab: https://t.co/ccyHcYCEKl @FierceBiotech @EisaiUS @Biogen #Alzheimers #mentalhealth #drugdiscovery #medicine
— NCBCenter (@NCBCenter) March 27, 2019
@Eisai_SDGs, @biogen kick-off phase 3 testing early #Alzheimer's disease antibody, amid dropping #aducanunab trial https://t.co/jmNie2FFf8 pic.twitter.com/8PFtoy4mgr
— Pharmacutical Daily (@PharmacDaily) March 22, 2019
https://twitter.com/HeidiCreighton/status/1109772708148113409
https://twitter.com/HeidiCreighton/status/1109064555542523906
Disappointing news, @biogen and Eisai have announced the decision to discontinue the EMERGE and ENGAGE Phase III clinical studies of #aducanumab in #Alzheimer’s diseasehttps://t.co/b0pCqyNZFc pic.twitter.com/uZjfSsaCwL
— Alzheimer Europe (@AlzheimerEurope) March 21, 2019
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease https://t.co/9aYlZeFYCV @biogen @EisaiUS More life science business news at [LSUS] at https://t.co/WILuBJwPqp pic.twitter.com/a4tJEPaJ1m
— [iito] Life Science (@iitoLifeScience) March 21, 2019
“We used to have to squint and look at things to feel like, ‘OK, maybe this could work.’ I think this is really giving us a real feeling that we’re making a lot of progress,” PMC's Dr. David Wolk told @whyy regarding the @biogen/Eisai research results. https://t.co/cKjfs4vtDN
— Penn Memory Center (@Penn_Memory) July 31, 2018
Eisai Co. & @Biogen revealed data showing their experimental drug slows the progression of #Alzheimers, but experts like PMC Co-Director @jasonkarlawish say they would like to see a larger, longer study conducted to further assess risks and benefits. @WSJ https://t.co/L1e06YnWjn
— Penn Memory Center (@Penn_Memory) July 30, 2018
.@biogen and Eisai's #Alzheimers drug demonstrated in a clinical trial that it significantly slowed cognitive decline and more for #pharma #marketers to know. $BIIB $GILD $AMGN #healthcare #HealthInsurance https://t.co/QebzaE0NAb pic.twitter.com/zHPfvrOsBx
— MM+M Magazine (@MMMnews) July 26, 2018
News for #pharma #marketers: Thurs, July 26
– @biogen and Eisai's #Alzheimers drug slows cognitive decline
– @GileadSciences CEO to step down
– @Amgen #migraine treatment faces difficulties with insurers$BIIB $GILD $AMGN #healthcare #HealthInsurance https://t.co/QebzaDJcID pic.twitter.com/p8HskyIm4K— MM+M Magazine (@MMMnews) July 26, 2018
.@Biogen and Japanese drugmaker Eisai created a surge in hope for an experimental #Alzheimers drug called BAN2401, after the companies announced positive results in a late-stage trial. But did the market overreact to the #data? #pharma #healthcare https://t.co/FlAEq43bX5 pic.twitter.com/KWgtEpyMsO
— MM+M Magazine (@MMMnews) July 14, 2018
Eisai and Biogen's Alzheimer's drug slows progression in Phase 2 trials https://t.co/q34CgTkBpR #AlzheimersDisease #Alzheimers #Phase2 @EisaiUS @biogen
— Pharmafocus (@Pharmafocus) July 26, 2018
Looks like Investors, analysts remain to be convinced over @EisaiUS @Biogen's #BAN2401 in #AlzheimersDisease even after more details of promising Phase II data
Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical https://t.co/YYao6VbYT2
— Ian Haydock (@ScripIanHaydock) July 26, 2018
Results of @Biogen and #Eisai clinical trial show #Alzheimers treatment reduced buildups of amyloid plaque in the brain by 93% and slowed progression of the disease 30-47% https://t.co/NIOMoy3SYG $BIIB pic.twitter.com/fwfkvkWzSM
— Jeff Cotrupe (@jeffcotrupe) July 25, 2018
Clinical trial results are in! Eisai & Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months @biogen https://t.co/kaoS6IQKJR pic.twitter.com/4glbrp4Hc7
— Neural Cell News (@NeuralCell) July 13, 2018
Eisai and @Biogen announce positive phase 2 Alzheimer’s data on BAN2401 anti-amyloid beta protofibril antibody. Patients exhibited slowdown in symptoms and reduced plaque in the brain. https://t.co/19Vp6MgFLI Good news and verification of amyloid beta as a therapeutic target
— Upperton (@UppertonLtd) July 12, 2018
We're closer than ever to treating #Alzheimer's with two drugs from @Biogen and @Eisai that do what #BigPharma hasn't been able to yet. https://t.co/uEccuWjPRX
— Tech2 (@tech2eets) July 10, 2018
@EisaiUS and @biogen Phase 2 trial for BAN2401 in #Alzheimers #patients, GlobalData figures say the global Alzheimer’s market will reach $14.8bn by 2026, so Eisai and Biogen can still expect to achieve significant sales for their product. https://t.co/mNRhbYywLU
— GlobalData Pharma (@Pharma_GD) July 6, 2018
@biogen @EisaiUS news – a win for the #amyloid hypothesis "BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack" via @PharmaScrip #Alzheimers pic.twitter.com/b7Srr8hCf6
— OptimumComms (@OptimumComms) July 6, 2018
https://twitter.com/akalali/status/1015103726577639424
#Eisai – #Biogen to advance #Alzheimers drug, provide fresh hope https://t.co/UHQLpoVTGA #ETHealthworld @ETHealthWorld @biogen #BAN2401 #AlzheimersDisease #pharma
— Plexus Ventures (@PlexusVentures) July 25, 2018
@biogen takes up option to co-develop #Eisai #AD drug https://t.co/mfwmLP2VXu @PharmaTimes #AlzheimersDisease #aducanumab
— Plexus Ventures (@PlexusVentures) October 25, 2017
Eisai sells RTP facility to @Biogen; results in 35 layoffs http://t.co/iqBdzh1Ski pic.twitter.com/m7S3Xolkzy
— Boston Business Journal (@BosBizJournal) July 16, 2015
#Leukemia_Therapeutics_Market: Growing at a CAGR of 6.6% over the forecast period of 2019-2025.
For More Details: https://t.co/jmnagRx2bn @Celgene @Eisai_SDGs @SanofiGenzyme @bmsnews @Novartis_AG @biogen @Roche @GSK @pfizer pic.twitter.com/BtaRV399Eb— Infinium Global Research (@infiniumglobal1) August 24, 2019
Very interesting consensus white paper from @MichaelJFoxOrg: A proposed roadmap for #Parkinsons proof of concept clinical trials investigating compounds targeting alpha synuclein – @biogen @VAInstitute @Eisai @LumosPharma @JCedarbaum @BrundinPatrikhttps://t.co/5h4mu4a70F pic.twitter.com/ozaqisV10M
— ScienceofParkinsons (@ScienceofPD) November 8, 2018
Would this treatment resolve these issues from #Inflammation as well?#Dementia @nih_nhlbi @biogen @EisaiUS @eisai @HopkinsMedNewshttps://t.co/V7k8ZwqTBd pic.twitter.com/79WFvREHz3
— BW (@fxrseen) July 6, 2018
Recent articles about Japan 日本関連英文記事 Vol.3
All the below tweets are in English.
Japan’s new prime minister, Yoshihide Suga, picked a status quo cabinet, suggesting he was rewarding the party factions behind his unexpected rise. But the number of women in the cabinet will also decline.https://t.co/R564uIvJjy
— The New York Times (@nytimes) September 17, 2020
The Japanese government has accused Greg Kelly of helping his former boss at Nissan, Carlos Ghosn, hide tens of millions of dollars of pay from regulators.
But when Kelly appeared in court on the opening day of his trial, he faced charges alone. https://t.co/fJm9qEEaae
— The New York Times (@nytimes) September 15, 2020
Since early July, Japan has allowed up to 5,000 fans at sporting and cultural events. The price of admission: follow strict rules and keep quiet. https://t.co/7MKFRE21eI
— The New York Times (@nytimes) September 14, 2020
Breaking News: Japan’s governing party has all but assured that Yoshihide Suga will become prime minister. Here’s what we know about Shinzo Abe’s successor. https://t.co/oBpcGKwWwX
— The New York Times (@nytimes) September 14, 2020
Japan’s new cabinet looks a lot like its old (male-dominated) cabinet https://t.co/CPrlBf7ZVO
— The Washington Post (@washingtonpost) September 16, 2020
The architects of Mario reflect on 35 years and the evolution of the franchise’s most iconic jump https://t.co/zVY6qXomRN
— The Washington Post (@washingtonpost) September 14, 2020
Japan ruling party elects Yoshihide Suga to succeed Shinzo Abe as prime minister https://t.co/pDsZ65Tud6
— The Washington Post (@washingtonpost) September 14, 2020
Japan’s new prime minister, Yoshihide Suga, will have a challenge ahead of him in how he deals with his relationship with both the U.S. and China, especially as tensions between the two escalate #WSJWhatsNow pic.twitter.com/uzHz0Y3vF4
— The Wall Street Journal (@WSJ) September 16, 2020
The era of Japan's Shinzo Abe is over, with Yoshihide Suga elected prime minister in the first leadership change since 2012 https://t.co/ZZGxpsQFjN
— The Wall Street Journal (@WSJ) September 16, 2020
Suga was elected Japan’s prime minister, as the country seeks to emerge from the coronavirus pandemic and navigate rising U.S.-China tensions https://t.co/NTdZh5yTmm
— The Wall Street Journal (@WSJ) September 16, 2020
On trial in Tokyo, Greg Kelly, Carlos Ghosn's former confidant at Nissan, made clear that, far from blaming his former boss for his troubles, he would serve as a spokesman for the good he believed Ghosn brought to Japan https://t.co/JBZnbyp8Ye
— The Wall Street Journal (@WSJ) September 15, 2020
Greg Kelly, the former Nissan executive charged with helping hide Carlos Ghosn’s compensation, pleaded not guilty at the opening of his trial in Tokyo #WSJWhatsNow pic.twitter.com/a2ZQHprAKC
— The Wall Street Journal (@WSJ) September 15, 2020
Heard on the Street: Japan’s incoming prime minister may pursue many of the same policies as his predecessor, but there are opportunities for serious improvements https://t.co/T7SVotd8PC
— The Wall Street Journal (@WSJ) September 15, 2020
Former Nissan executive Greg Kelly pleaded not guilty to helping Carlos Ghosn hide compensation as his trial gets under way in Tokyo https://t.co/i9RWIQtTqF
— The Wall Street Journal (@WSJ) September 15, 2020
Naomi Osaka won the U.S. Open women’s title—and made a simple statement of protest that will be long remembered, writes @jasongay https://t.co/pmg3QuM3gA
— The Wall Street Journal (@WSJ) September 14, 2020
Before he got Japan’s top government job officially, Yoshihide Suga was known as a “shadow” prime minister and right-hand man to his long-serving predecessor. https://t.co/LOUDGUTU0G
— Los Angeles Times (@latimes) September 16, 2020
Livestock ship carrying 42 crew sinks off Japan’s coast https://t.co/ZvP6uD4lGn
— AJC (@ajc) September 3, 2020
Japan PM Shinzo Abe resigning for health reasons https://t.co/cEG9KBeHSh
— AJC (@ajc) August 28, 2020
BREAKING: Japan floods leave up to 34 dead, many at nursing homes https://t.co/qkE27IPOle
— AJC (@ajc) July 5, 2020
#BREAKING: Japan’s PM says IOC has agreed to delay Olympics for one year. https://t.co/URu4XeHgHr pic.twitter.com/qtpC3CFjKl
— AJC (@ajc) March 24, 2020
Yoshihide Suga was elected as the new head of Japan’s ruling party on Monday, virtually guaranteeing him parliamentary election as the country’s next prime minister. https://t.co/ktz8wEqcBm
— The Boston Globe (@BostonGlobe) September 14, 2020
Philly activists help launch American-style capitalist attack in corporate Japan https://t.co/rLo6cqFZEH
— The Philadelphia Inquirer (@PhillyInquirer) February 17, 2020
Several dozen aging U.S. veterans will gather on a battleship in Hawaii's Pearl Harbor next month to mark the 75th anniversary of Japan’s surrender in World War II, even if it means the vulnerable group may be risking their lives again amid a pandemic. https://t.co/43Z2CixhDt
— Chicago Sun-Times (@Suntimes) August 24, 2020
The sudden rise in the number of virus cases in Tokyo and the government’s strong actions immediately after the Olympic postponement have raised questions in parliament and among citizens about whether Japan understated the extent of the outbreak.https://t.co/mrhdXESYtQ
— Chicago Sun-Times (@Suntimes) March 30, 2020
In Japan, there are 13.1 hospital beds for every 1,000 people.
In the U.S., there are just 2.9 hospital beds per 1,000 people.
“If tens of thousands become sick at once, people will simply not receive the care that they need." https://t.co/8fcjncxyu3
— Chicago Sun-Times (@Suntimes) March 15, 2020
If the coronavirus threat continues, the games could be postponed until later in 2020, a statement from Japan’s Olympic minister implied Tuesday. https://t.co/eAz25dgjVP
— Chicago Sun-Times (@Suntimes) March 4, 2020
Trump downplays virus, attacks Biden, Japan's leader steps down and college towns struggle without students https://t.co/lw0Dr1EyvA
— St. Louis Post-Dispatch (@stltoday) August 28, 2020
A sudden rise in virus cases in Tokyo has raised questions about whether Japan understated the extent of its outbreak and delayed enforcement of social distancing measures while clinging to hopes that the Olympics would start on July 24 as scheduled. https://t.co/cUlvMs8kDE
— Star Tribune (@StarTribune) March 30, 2020
"I think we have to hold the games at any cost,” Japan's Olympic minister Seiko Hashimoto said Tuesday. “I want to concentrate all our efforts on measures against the coronavirus." https://t.co/or03jJxefU
— Des Moines Register (@DMRegister) September 9, 2020
On this date in 1945, the Enola Gay dropped an atomic bomb on Hiroshima, Japan. About 70,000 people were killed instantly by the explosion, which had a radius of around a mile. As many as 140,000 people ultimately died from the blast. https://t.co/A1fFWJzgxd
— Des Moines Register (@DMRegister) August 6, 2020
The @uiowa said it was canceling exchange programs in Japan "due to concerns about the ability of the host institutions to provide adequate health and safety infrastructure should the situation with COVID-19 deteriorate." https://t.co/35scIb1qfE
— Des Moines Register (@DMRegister) March 4, 2020
A talented photographer is capturing some amazing closeups of tiny creatures, a sunflower maze has been planted near the Fukushima nuclear disaster site in Japan to help absorb radiation, wolverines have returned to Mount Rainier National Park in… https://t.co/vN4ydsWL8S
— Omaha World-Herald (@OWHnews) August 21, 2020
Pounding rain and flooding battered large areas of Japan's main island, swelling rivers and destroying houses and roads. At least 58 people have died. https://t.co/ZbfLr5TUdU
— Omaha World-Herald (@OWHnews) July 8, 2020
Warren Jorgenson witnessed the attack on Manila at the outset of WWII. He was wounded just before the fall of Corregidor, endured a “hell ship” journey to Japan and spent 3 years as a POW. He died June 1 after a battle with #COVID19. More from @SteveLiewer https://t.co/1jtetAVA5P
— Omaha World-Herald (@OWHnews) June 14, 2020
Japanese Prime Minister Shinzo Abe and his Cabinet resigned, clearing the way for his successor to take over after parliamentary confirmation later Wednesday. https://t.co/6H3jIjHuX2
— The Denver Post (@denverpost) September 16, 2020
Naomi Osaka, a professional tennis player from Japan, wore an Elijah McClain face mask when she took the court Wednesday at the U.S. Open in New York City. https://t.co/ChVBRZsIeX
— The Denver Post (@denverpost) September 3, 2020
Other coronavirus hot spots like China, Iran, Japan, South Korea, Italy and western Washington are all located within similar latitudes to Colorado. https://t.co/UXIicIvzCT
— The Denver Post (@denverpost) March 17, 2020
Who is Japan's "quiet" new leader, and how will he work with Donald Trump, or Joe Biden? https://t.co/9Mr0AWxA58
— CBS News (@CBSNews) September 16, 2020
Yoshihide Suga has been elected Japan's new Prime Minister following a vote in the country's Parliament on Wednesday, confirming the former cardboard factory worker and farmer's son as leader of the world's third largest economy. https://t.co/oKi8HXbMaJ
— CNN International (@cnni) September 16, 2020
Japan's next Prime Minister?
Yoshihide Suga was voted in as the new leader of the ruling Liberal Democratic Party, securing about 70% of the votes, paving the way for the 71-year-old to become PM in a parliamentary vote on Wednesday https://t.co/YD47AGsdOr
— CNN International (@cnni) September 14, 2020
Yoshihide Suga elected as the new head of Japan’s ruling party, virtually guaranteeing him parliamentary election as the country’s next prime minister. https://t.co/V5tVxAc9lY
— ABC News (@ABC) September 14, 2020
NEW: Yoshihide Suga set to become Japan's new Prime Minister after PM Abe announced last month he was resigning due to health issues. https://t.co/OCsXm9XgZa
— NBC News (@NBCNews) September 14, 2020
Five takeaways from Japanese Prime Minister Suga’s new cabinet https://t.co/oiXofdFX6b
— Bloomberg Politics (@bpolitics) September 16, 2020
JUST IN: Japan’s parliament elects Yoshihide Suga as new prime minister https://t.co/cXftEY3Zvm
— Bloomberg Politics (@bpolitics) September 16, 2020
BREAKING: Japan's Yoshihide Suga is set to become the country's next prime minister after being elected leader of the ruling Liberal Democratic Party by an overwhelming majority https://t.co/fxh48gCd1z pic.twitter.com/8gVxNDqb2d
— Bloomberg Politics (@bpolitics) September 14, 2020
The front-runner to become Japan’s next prime minister repeated his calls for lower mobile phone fees ahead of elections this week https://t.co/g7ezqpzKmz
— Bloomberg Politics (@bpolitics) September 13, 2020
Yoshihide Suga, the front-runner to become Japan’s next premier, emphasizes the importance of the nation’s alliance with the U.S. https://t.co/OG8p4Z8nxu
— Bloomberg Politics (@bpolitics) September 13, 2020
Yoshihide Suga is a patient man https://t.co/EAdjqoh2qC
— Bloomberg Politics (@bpolitics) September 11, 2020
Yoshihide Suga, the leading candidate to become Japan’s next leader, says he sees no sales tax hike in the next 10 Years https://t.co/qAkoEtQPXK
— Bloomberg Politics (@bpolitics) September 11, 2020
The conservative majority Liberal Democratic Party (LDP) of Japan elected departing Japanese Prime Minister Abe Shinzo’s chief cabinet secretary, Suga Yoshihide, its president on Monday. https://t.co/DbbuiLrJ7x
— Breitbart News (@BreitbartNews) September 15, 2020
What’s Next for the U.S.–Japan ‘Special Relationship’ | https://t.co/zPPEQrWns2 via @ArthurLHerman pic.twitter.com/SZeCtZqzE2
— National Review (@NRO) August 27, 2020
Japan’s Economy Shrinks at a Record 7.8 Percent https://t.co/WW84e5TOyE pic.twitter.com/T5AvDpwE2p
— National Review (@NRO) August 18, 2020
A Lesson from Japan’s Fight against Coronavirus: Masks Help | https://t.co/qqCQLmQYZf via Linda Halderman pic.twitter.com/g3pUus7H2l
— National Review (@NRO) March 31, 2020
“Washington must do all that it can to support Japan’s next captain as he assumes the tiller to maintain a steady course.” https://t.co/5EM0E1pbtN
— Heritage Foundation (@Heritage) September 2, 2020
https://twitter.com/HudsonInstitute/status/1273284986150563841
https://twitter.com/ColumbiaSIPA/status/1304085453952483328
Abe left Japan's Liberal Democratic Party in a good position politically, thus his successor will step into the prime minister’s office with a strong legislative foundation from which to govern, writes @sheilasmithcfr https://t.co/c5h4a2iKCo
— Council on Foreign Relations (@CFR_org) September 11, 2020
In @ForeignPolicy, @sheilasmithcfr highlights three challenges Japan's next prime minister will face: https://t.co/YnAZhrdwll
— Council on Foreign Relations (@CFR_org) September 8, 2020
On this day in 1945, Japan signed a formal surrender, officially ending World War II. Trace the last days of Imperial Japan in this timeline. https://t.co/OvjDVIgcBR
— Council on Foreign Relations (@CFR_org) September 2, 2020
Today marks 75 years since the Allied occupation of Japan began, under which the country's new constitution was created.
Today, Japan is debating whether to amend that war-renouncing constitution for the first time. Here's what that could mean. https://t.co/ViUQjITaZu pic.twitter.com/JcXPxmHEeE
— Council on Foreign Relations (@CFR_org) August 31, 2020
The 2020 Summer Olympics in Tokyo have been postponed, but Japan is still working around the clock to preserve them. Is it worth it?
— Council on Foreign Relations (@CFR_org) July 24, 2020
Japan has escaped the high COVID-19 infection levels seen elsewhere, but its economy has still been hit hard. What can Suga do?https://t.co/jzC9n4tck7
— Foreign Policy (@ForeignPolicy) September 15, 2020
When it comes to Japan’s more muscular approach to foreign policy, Suga may not be Abe’s most aggressive steward, FP's @JackDetsch writes.https://t.co/UQ0wRAu0wF
— Foreign Policy (@ForeignPolicy) September 15, 2020
Incoming Japanese Prime Minister Yoshihide Suga has already made clear that his goal is stability, not innovation.https://t.co/LzxWZlgpkp
— Foreign Policy (@ForeignPolicy) September 14, 2020
Shinzo Abe’s successor will be chiefly preoccupied with three challenges: Japan’s coronavirus pandemic-related economic fallout, national security, and its rapidly-aging population, Sheila A. Smith writes. https://t.co/Hwgjq5cdMP
— Foreign Policy (@ForeignPolicy) September 12, 2020
A relationship that was near its peak in 2012 is now at a nadir since Japan and South Korea normalized their diplomatic relationship in 1965, S. Nathan Park writes.https://t.co/AhhgcvRTCz
— Foreign Policy (@ForeignPolicy) September 9, 2020
At the core of Abe’s foreign policy was the alliance with the United States, Michael Auslin writes. The great question for Japan, of course, is who succeeds Abe and what will they do with his policies? https://t.co/1A76azxpGy
— Foreign Policy (@ForeignPolicy) August 31, 2020
Last year, William Sposato wrote about Japanese Prime Minister Shinzo Abe, and how his cherished personal goal of shedding the pacifist nature of Japan’s postwar constitution seemed just out of reach. From our archives:https://t.co/EdU0ixwXG9
— Foreign Policy (@ForeignPolicy) August 28, 2020
For the past 75 years, the American postwar military occupation of Japan has served as a model for how the U.S. might dominate global battlefields. But this precedent is far more fraught than it appears, writes Marc Gallicchio https://t.co/lcCzzEsARi
— Foreign Policy (@ForeignPolicy) August 16, 2020
Japan’s cancellation of the Aegis Ashore ballistic missile defense system, while primarily motivated by the high cost, was also inspired by opposition by community members who feared the health effects of the weapon, Jeffrey W. Hornung writes. https://t.co/F4LaosW7Pa
— Foreign Policy (@ForeignPolicy) July 2, 2020
Japan’s labor shortage forced the country to increase its immigration numbers, showing that it’s possible to accept immigrants without political backlash.https://t.co/5SvQ5QzIBr
— Foreign Policy (@ForeignPolicy) June 25, 2020
In Japan, South Korea and Taiwan, state-led nuclear energy development took place during the political dominance of conservative parties. As liberal parties begin taking control in these nations, anti-nuclear sentiment is rising. https://t.co/NGZmaNoZGp
— Foreign Policy (@ForeignPolicy) June 20, 2020
Yukio Okamoto died from complications due to the coronavirus. His death is not only a personal tragedy, but also a huge loss to the future of U.S.-Japan relations. https://t.co/K0L8ucWWsi
— Foreign Policy (@ForeignPolicy) May 22, 2020
With among the lowest death rates in the world, a medical system that has avoided an overloading crisis, and a declining number of cases, everything seems to be going oddly right in Japan.https://t.co/aoJn7fjP2d
— Foreign Policy (@ForeignPolicy) May 15, 2020
Japan's coronavirus success remains a mystery.https://t.co/aoJn7fjP2d
— Foreign Policy (@ForeignPolicy) May 14, 2020
Japan will soon discover whether its workaholic company employees will now see that their moral duty is to stay home.https://t.co/ADGB33Qu4n
— Foreign Policy (@ForeignPolicy) April 10, 2020
Japanese ruling party leader Yoshihide Suga was elected prime minister in a parliamentary vote Wednesday, becoming the country’s first new premier in nearly eight years https://t.co/E6qgh4kt88
— TIME (@TIME) September 16, 2020
"It’s hard to call Abe a transformational leader,” writes @ianbremmer. “But just because Abe failed to be a transformative politician hasn’t made him a failed one.” https://t.co/s9LSpBa3c6
— TIME (@TIME) September 11, 2020
Japanese Prime Minister Shinzo Abe’s successor must deal with a stricken economy, an increasingly bellicose China and North Korea, an unpredictable White House and a ticking demographic time bomb https://t.co/GMiaJBAyrr
— TIME (@TIME) September 8, 2020
Japanese Prime Minister Shinzo Abe and his Cabinet resigned, clearing the way for his successor to take over after parliamentary confirmation later Wednesday https://t.co/ORJAXUD9Yn
— POLITICO (@politico) September 16, 2020
Japan's governing party picks Yoshihide Suga as next prime minister https://t.co/0FAIen2y5q pic.twitter.com/sTFpyDtI9w
— The Hill (@thehill) September 16, 2020
Japan's Olympics minister: "I think we have to go ahead with the Games" https://t.co/froF2TG8Oc pic.twitter.com/6kklbN4F5d
— The Hill (@thehill) September 8, 2020
Recent articles about Japan 日本関連英文記事 Vol.2
All the below tweets are in English.
Japan's economy minister instructed by new PM to take steps without hesitation https://t.co/SiCJ1ZTnFU pic.twitter.com/lFsQdM8851
— Reuters (@Reuters) September 17, 2020
Japan's reappointed finance minister Aso says will prod regional banks to pursue reforms https://t.co/WAZp0v2BNV pic.twitter.com/4WuhopXYo3
— Reuters (@Reuters) September 17, 2020
BOJ to hold fire, signal resolve to work closely with Suga's new cabinet https://t.co/yqw5rAjbSZ pic.twitter.com/dTr8OriSFV
— Reuters (@Reuters) September 17, 2020
Japan's longest-serving prime minister Shinzo Abe left office amid applause before his longtime aide Yoshihide Suga was voted prime minister by parliament https://t.co/hKCJX4sWIZ pic.twitter.com/VYrTnrLJJp
— Reuters (@Reuters) September 16, 2020
Japan’s new Prime Minister Yoshihide Suga said he would stick with his former boss’ 'Abenomics' growth policies while pushing reforms https://t.co/PFUWnSF9bC pic.twitter.com/4tlbtLOFFM
— Reuters (@Reuters) September 16, 2020
From @Breakingviews: Japan has a new prime minister after nearly eight years. Yoshihide Suga, the tight-lipped technocrat, will need to shed some of his stern demeanor to lead the country out of recession, says @petesweeneypro pic.twitter.com/eWji7cC9sE
— Reuters (@Reuters) September 16, 2020
Telefonica partners with Japan's Rakuten to develop open 5G network https://t.co/FQtFzQyIMf pic.twitter.com/BNsFRXUpkh
— Reuters (@Reuters) September 16, 2020
China says it hopes Japan will not develop official ties with Taiwan https://t.co/S8aWZPP07W pic.twitter.com/IxK1g8HGVh
— Reuters (@Reuters) September 16, 2020
Japan’s Yoshihide Suga was voted prime minister by parliament to become the country’s first new leader in nearly eight years, appointing a new cabinet that kept about half of the familiar faces from predecessor Shinzo Abe’s lineup https://t.co/e9YG3w6TL6
— Reuters (@Reuters) September 16, 2020
Japan's exports extend double-digit declines as pandemic hits demand https://t.co/e3kNHS0rOJ pic.twitter.com/wJKcX7OBE1
— Reuters (@Reuters) September 16, 2020
Japan defence minister Kono to become internal affairs min in new cabinet: Kyodo https://t.co/PH4IqpQmUo pic.twitter.com/C75zhyYPEc
— Reuters (@Reuters) September 15, 2020
After sweeping party poll, Japan's Suga faces tricky call on snap election https://t.co/hXKdA0zFZb pic.twitter.com/yYvm4vUcQP
— Reuters (@Reuters) September 15, 2020
Japan's Aso says should consider early dissolution of parliament https://t.co/PI5GGsIn5T pic.twitter.com/0UQwnnEols
— Reuters (@Reuters) September 15, 2020
Japan's new leadership agenda could make jobs a bigger BOJ priority https://t.co/jfL67MCYVv pic.twitter.com/DjgE1y38Dv
— Reuters (@Reuters) September 15, 2020
Japan ruling party head Suga preparing cabinet, continuity in foreground https://t.co/4WcznGiSY5 pic.twitter.com/2FJqlXeXJ1
— Reuters (@Reuters) September 15, 2020
Japan health minister Kato likely to replace Suga as chief cabinet secretary: Nippon TV https://t.co/ErdsJudoE6 pic.twitter.com/LDsrJGTs6n
— Reuters (@Reuters) September 15, 2020
From @Breakingviews: Nvidia will buy UK-based chip designer Arm from Japan’s SoftBank Group and its growth will depend on winning over many of Arm’s customers like Intel, which compete with Nvidia, as well as anti-trust regulators around the world, @LiamWardProud says pic.twitter.com/kmcEjAooNu
— Reuters (@Reuters) September 15, 2020
United Airlines to close Japan's Narita hub, affecting 270 jobs: NHK https://t.co/OqmpLBQHfu pic.twitter.com/x2n3OOKtWU
— Reuters (@Reuters) September 14, 2020
Japan's Suga wins ruling party leadership race to replace Abe https://t.co/zs7oL16itL pic.twitter.com/zsSHbVTY38
— Reuters (@Reuters) September 14, 2020
Japan’s Yoshihide Suga wins ruling party leadership election, paving the way for him to become prime minister in a parliamentary vote this week https://t.co/YRwm9K9Int pic.twitter.com/3v3Mf1JIOr
— Reuters (@Reuters) September 14, 2020
Japan's next prime minister as a boy: good in sports, 'stiff' as actor https://t.co/92zlCQfyYQ pic.twitter.com/3UKmjxhTkO
— Reuters (@Reuters) September 14, 2020
Factbox: Japan next premier's hometown: demographic challenges by the numbers https://t.co/1QTxKQCVxG pic.twitter.com/uYzx0b55Te
— Reuters (@Reuters) September 14, 2020
Japan's Suga says no limit to bonds government can issue https://t.co/3UiYqHO5yH pic.twitter.com/pMLXlXn8Aa
— Reuters (@Reuters) September 13, 2020
Japan's Suga says no limit to bonds government can issue https://t.co/47gMZ8iSS1 pic.twitter.com/1Z6Zr4GW3H
— Reuters (@Reuters) September 13, 2020
Osaka 'a Jesse Owens of Japan' for racial injustice stand https://t.co/imj7cYQq6T pic.twitter.com/sz0sVBx8j1
— Reuters (@Reuters) September 12, 2020
Hip hop hooray for Japan's next PM with hometown T-shirt shout-out https://t.co/AoHablSyRd pic.twitter.com/PDxTZiwS7N
— Reuters (@Reuters) September 12, 2020
Japan's Suga, likely next PM, says ready to top up payouts to ease COVID-19 pain https://t.co/3I5JpaJRM1 pic.twitter.com/271DkXf312
— Reuters (@Reuters) September 12, 2020
Japan's Suga seeks solid communications with Asian neighbors https://t.co/dTL3DCFEJK pic.twitter.com/1iEUL3WkjB
— Reuters (@Reuters) September 12, 2020
Tiffany gets regulatory nod from Japan, Mexico for troubled LVMH deal https://t.co/VqNr9haIIm pic.twitter.com/Dn4jrGvVPh
— Reuters (@Reuters) September 11, 2020
Abe plan for land-attack counterpunch could mark major military shift for Japan https://t.co/N3f7XG0xhq pic.twitter.com/CFgEMjmg4A
— Reuters (@Reuters) September 11, 2020
UK and Japan strike Britain's first post-Brexit trade deal https://t.co/KTn04NK77g pic.twitter.com/BxaqsrdWbx
— Reuters (@Reuters) September 11, 2020
Japan's new government should focus on response to coronavirus, digitalization: Reuters poll https://t.co/1rmBToSQ86 pic.twitter.com/2PacSUBneb
— Reuters (@Reuters) September 11, 2020
Japan foreign minister says aims to reach broad agreement on UK trade deal Friday https://t.co/lIXpIorFrb pic.twitter.com/BvA9E7BOZl
— Reuters (@Reuters) September 11, 2020
Japan firms plan to cut capex by 6.8% this fiscal year: survey https://t.co/cjgobzhKJO pic.twitter.com/yQzvX3gUgg
— Reuters (@Reuters) September 11, 2020
Japan's Suga: Will have to call for sales tax hike in future https://t.co/4P8FLYxHCw pic.twitter.com/SRlShwBXgo
— Reuters (@Reuters) September 10, 2020
Stuck at home for weeks while Japan was under a state of emergency due to the coronavirus, renowned Japanese Bunraku puppet master Kanjuro Kiritake, all his performances canceled for months, was stricken with deep anxiety https://t.co/ITent24Oip
— Reuters (@Reuters) September 10, 2020
Yoshihide Suga, on course to become Japan’s next prime minister, said he would maintain incumbent premier Shinzo Abe’s policy prioritizing economic growth over efforts to fix the country’s tattered finances https://t.co/n0731rDKOc
— Reuters (@Reuters) September 9, 2020
Exclusive: Japan ruling coalition partner Komeito indicates it does not want snap election https://t.co/oEcSPCorwu pic.twitter.com/fuompQDij9
— Reuters (@Reuters) September 9, 2020
Japan's households, firms keep hoarding cash at record pace as COVID-19 strains broaden https://t.co/rLbJKNkW0A pic.twitter.com/pLs5P2Re3o
— Reuters (@Reuters) September 9, 2020
Japan's Suga in pole position for PM as debate kicks off https://t.co/AWXlIX2ibM pic.twitter.com/H5UMOlUlFr
— Reuters (@Reuters) September 9, 2020
Japan's Suga says important to cover fertility treatment by national insurance https://t.co/8xeoz2tlgy pic.twitter.com/8XDyhPHQJa
— Reuters (@Reuters) September 9, 2020
Japan’s economy shrank by over 28% in the second quarter as the global crisis had businesses struggling more than initially thought, underscoring the daunting task the new prime minister faces in averting a steeper recession https://t.co/WGdKT6Sbrd pic.twitter.com/fi2eOCJQ2X
— Reuters (@Reuters) September 8, 2020
Japan's Chief Cabinet Secretary Yoshihide Suga, a frontrunner to succeed Prime Minister Shinzo Abe, could call a snap election to solidify his political grip if he becomes the country's next premier https://t.co/mN5FBhmnnE pic.twitter.com/pH5vQRfS81
— Reuters (@Reuters) September 8, 2020
Tokyo 2020 Olympics organisers have not extended sponsors’ contracts set to expire at the end of the year, sources said, leaving some questioning whether to continue after COVID-19 forced a delay of the world’s largest sporting event https://t.co/e51BZ3IRaD
— Reuters (@Reuters) September 8, 2020
Factbox: Continuity and reforms: Japan PM hopeful Suga's key policies https://t.co/Gr20nDT77C pic.twitter.com/NXxZB5a5tP
— Reuters (@Reuters) September 8, 2020
Japan defence chief Kono expects to be prime minister one day, but backs Suga to succeed Abe https://t.co/DD2zcP0akQ pic.twitter.com/UtWRxXKs1T
— Reuters (@Reuters) September 3, 2020
Japan LDP heavyweight Kishida: Frank discussions needed with U.S. over defence burden https://t.co/7Hq6jQl89v pic.twitter.com/bgteKbqja5
— Reuters (@Reuters) September 2, 2020
Japan former foreign minister Kishida announces candidacy to succeed PM Abe https://t.co/KAJ37IIfMb pic.twitter.com/qMr56YBcHi
— Reuters (@Reuters) September 1, 2020
Japan's PM candidate Kishida cautious about cutting sales tax https://t.co/c2rpGAR3j5 pic.twitter.com/eQ4ijGJ9LI
— Reuters (@Reuters) August 31, 2020
Japan Defence Minister Kono says still undecided on run for ruling party leadership https://t.co/RIOCsS4eR8 pic.twitter.com/mL7SYNzqWs
— Reuters (@Reuters) September 1, 2020
Ex-defence minister Ishiba is people's choice for next Japan PM: polls https://t.co/vz2wwRC27L pic.twitter.com/FDUz78EpgK
— Reuters (@Reuters) August 31, 2020
Japan's Koizumi won't seek to succeed Abe as PM, would back Kono – NHK https://t.co/qkqUEYeUkN pic.twitter.com/sD38jEwhIV
— Reuters (@Reuters) August 30, 2020
Japan’s Sumitomo Corp. exits U.S. shale gas industry. via @Reuters https://t.co/wowqaMYt5d
— IEEFA_AsiaPacific (@IEEFA_AsiaPac) September 10, 2020
BREAKING: Yoshihide Suga has been formally elected Japan’s prime minister in a parliamentary vote. Suga was long the right-hand man to his predecessor, Shinzo Abe, who was Japan’s longest-serving prime minister. https://t.co/p6Ux2TPe3w
— The Associated Press (@AP) September 16, 2020
Yoshihide Suga has been elected as the new head of Japan’s ruling party, virtually guaranteeing him parliamentary election as the country’s next prime minister. https://t.co/Qjb7UPKAPp
— The Associated Press (@AP) September 14, 2020
Japanese prime minister hopeful Yoshihide Suga says he lacks the kind of diplomatic skills that outgoing leader Shinzo Abe has, including Abe's personal friendship with President Trump, and that he will need his assistance if he assumes the top job. https://t.co/Z176gjbjIN
— The Associated Press (@AP) September 12, 2020
https://twitter.com/AFP/status/1306237603637874688
#UPDATES Japan's parliament elects Yoshihide Suga prime minister, with the former chief cabinet secretary expected to stick closely to policies championed by Shinzo Abe during his record-breaking tenure https://t.co/BsfvhxSd6V pic.twitter.com/YXORmDXKA9
— AFP news agency (@AFP) September 16, 2020
Japan's parliament votes today for the country's next prime minister, with powerful cabinet secretary Yoshihide Suga all but assured the top jobhttps://t.co/8wZhfDupzw pic.twitter.com/ULPxi84Riw
— AFP news agency (@AFP) September 16, 2020
VIDEO: Japan's chief cabinet secretary Yoshihide Suga pledges a continuation of Shinzo Abe's policies as he is elected as the ruling party's new leader, making him all but certain to become the country's next prime minister pic.twitter.com/Utn5ZAoruf
— AFP news agency (@AFP) September 15, 2020
VIDEO: Japan ruling party elects Yoshihide Suga as PM successor.
The vote makes Suga all but certain to replace Shinzo Abe as the country's next prime minister pic.twitter.com/l9dfDW0Wee
— AFP news agency (@AFP) September 14, 2020
Japan's ruling party votes today for its next leader, with top government adviser Yoshihide Suga all but certain to win and replace Shinzo Abe as the country's new prime ministerhttps://t.co/yXRA6YPdmV pic.twitter.com/wRzMpvdWNV
— AFP news agency (@AFP) September 14, 2020
Japan's Yoshihide Suga to formally take up PM job, announce 'continuity' cabinet https://t.co/lCq86q9598 pic.twitter.com/8TVMcOF1tS
— FRANCE 24 (@FRANCE24) September 16, 2020
Japan's Yoshihide Suga wins leadership race to succeed outgoing PM Shinzo Abe https://t.co/XJCoFr5ful pic.twitter.com/wS6Dbftjiu
— FRANCE 24 (@FRANCE24) September 14, 2020
https://twitter.com/France24_fr/status/1305432334355902464
https://twitter.com/France24_en/status/1305441224132898817
https://twitter.com/i_montaigneEN/status/1305157795155714049
Concerns about the US’ readiness and ability to fulfill its security commitments have led Japan to enact security reforms to enhance its value as an ally while moving toward a more autonomous defense posture to prepare for the worst-case scenario.
➡️ https://t.co/CPn7pN2wRD pic.twitter.com/9aIPHUl32E
— IFRI (@IFRI_) July 24, 2020
In Japan, language is an integral part of a vertical society in which submission is a virtue. Japanese has different words for addressing a superior, a colleague or a sibling, which signal their place in society.https://t.co/1huvL32KBl
— Le Monde diplomatique in English (@LMdiplo) September 13, 2020
Years after the tsunami that swept northeast Japan, towns are being rebuilt. But will their inhabitants return, and should they? Fukushima’s toxic legacy will last for decades.
(September: the longer view.)https://t.co/MD2pzQ0djt
— Le Monde diplomatique in English (@LMdiplo) September 13, 2020
Yoshihide Suga won Japan's ruling party leadership race, virtually guaranteed to become the country's next prime minister. https://t.co/XLmF1dJ6ss
— DW News (@dwnews) September 14, 2020
Recent articles about Japan (mainly on new cabinet) 主に新内閣発足についての日本関連英文記事 Vol.1
All the below tweets are in English.
日本関連ツイートを拾うことは通常どおり特にしない予定でしたが、Reuters社を中心に以前よりは数が増えている感触があるので、前回投稿分以降の日付のものを中心にざぁっとですが拾ってみました。３回に分けて投稿します。
While I have not intended to collect news articles mainly on Japan’s new cabinet, I have come to confirm that there are more articles – mainly by Reuters – related to such issues than before as I have thought. That is why I collected roughly and posted here mainly tweets after the last post (Sep 8). This is the first of the three posts this time.
Hitachi to pull plug on north Wales nuclear power station https://t.co/9UiBT8ivbX
— The Guardian (@guardian) September 15, 2020
A Japan trade deal is little consolation if Britain is locked out of the EU https://t.co/VFXzXABLgg
— The Guardian (@guardian) September 13, 2020
Japan trade deal is small beer – but a welcome distraction https://t.co/PYes0nZkXr
— The Guardian (@guardian) September 11, 2020
UK government hails 'historic' trade deal with Japan https://t.co/tCu1vE1VHZ
— The Guardian (@guardian) September 11, 2020
Tokyo Olympics must be held at 'any cost', says Japanese minister https://t.co/s3iKj7upPC
— The Guardian (@guardian) September 8, 2020
Yoshihide Suga emerging as favourite to become Japan's prime minister https://t.co/kvdxwSftOD
— The Guardian (@guardian) September 1, 2020
#FPCJ #japannews @guardian
Yoshihide Suga to be Japan's prime minister after winning party vote https://t.co/NvynYefFBG— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 15, 2020
#FPCJ #japannews @guardian
Yoshihide Suga: the farmer's son set to be Japan's next PM https://t.co/LNojbwYdMz— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 14, 2020
Yoshihide Suga was elected Japan’s new prime minister in a parliamentary vote, following the resignation of Shinzo Abe https://t.co/3topdlCjap
— The Telegraph (@Telegraph) September 16, 2020
Who is Yoshihide Suga, the new Prime Minister of Japan? https://t.co/s885naHuXp
— The Independent (@Independent) September 16, 2020
Yoshihide Suga formally elected as Japan’s new prime minister https://t.co/3JhhviQCOW
— The Independent (@Independent) September 16, 2020
Yoshihide Suga: The unexpected rise of Japan’s new prime minister https://t.co/VbOcBegU78
— BBC News (World) (@BBCWorld) September 16, 2020
Yoshihide Suga elected Japan's new prime minster succeeding Shinzo Abe https://t.co/ifNL6ETIOn
— BBC News (World) (@BBCWorld) September 16, 2020
Yoshihide Suga: The strawberry farmer's son on track to be Japan's PM https://t.co/QrvbOikYnt
— BBC News (World) (@BBCWorld) September 14, 2020
#FPCJ #japannews @BBCWorld
BBC News – Yoshihide Suga: The strawberry farmer's son on track to be Japan's PM https://t.co/t8t07LBXBr— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 15, 2020
Japan's new prime minister Yoshihide Suga promises to turn round economy after succeeding Shinzo Abe https://t.co/GR4b8Dk1tf
— SkyNews (@SkyNews) September 16, 2020
Yoshihide Suga is set to become Japan's new prime minister, following the resignation of Shinzo Abe https://t.co/iWjgw5zvB7
— SkyNews (@SkyNews) September 14, 2020
Each year, the Japanese drink enough ready-to-drink coffee to fill Tokyo’s new Olympic Stadium almost to the brim https://t.co/rz81kHc1J0
— The Economist (@TheEconomist) September 16, 2020
Japan's shrinking and ageing population is stoking the demise of rural railway lines https://t.co/pXlPOztwDu
— The Economist (@TheEconomist) September 16, 2020
Suga Yoshihide secured the support of Japan’s ruling Liberal Democratic Party by pledging continuity and stability at a time of crisis https://t.co/pPcvZVPBXe
— The Economist (@TheEconomist) September 15, 2020
Today on “The Intelligence”: Japan’s new prime minister, the state of the World Health Organisation and the great canine schism among Egypt’s clerics https://t.co/xDPKcE3gSE
— The Economist (@TheEconomist) September 15, 2020
If Japan's next prime minister succeeds, it will be thanks in large part to the groundwork laid by Abe Shinzo https://t.co/SALMLrrYPp
— The Economist (@TheEconomist) September 6, 2020
Many have cast Abe Shinzo's resignation as an admission of defeat. But Japan's outgoing prime minister has done a far better job than is commonly acknowledged. Our cover in Asia this week https://t.co/epAEDInipU pic.twitter.com/PnzNEhbBHR
— The Economist (@TheEconomist) September 3, 2020
“It says: ‘Please attack us’,” complains a campaigner against a proposed military base in Japan https://t.co/abFed4jNNm
— The Economist (@TheEconomist) August 15, 2020
#lockdown giving you itchy feet? Over on our #blog, Dr Sonia Favi discusses how in the Tokugawa era, #maps provided a 'virtual' means of exploring and domesticating the Japanese territory, even when physical travel wasn’t possible https://t.co/5Aw3iZidtC @TheJohnRylands @UoMSALC pic.twitter.com/VMnnLZANu8
— JRRI (@JRRIManchester) July 6, 2020
Yoshihide Suga is not your typical Japanese politician and yet the 71-year-old son of a strawberry farmer is about to become Japan's next prime minister | @ErykBagshaw https://t.co/YdxLk4wGgn
— The Sydney Morning Herald (@smh) September 14, 2020
Shinzo Abe's chief cabinet secretary Yoshihide Suga is set to become Japan's next prime minister after winning a mandate to continue his predecessor's domestic and foreign policy | @ErykBagshaw https://t.co/L5ehz7jTpb
— The Sydney Morning Herald (@smh) September 14, 2020
Yoshihide Suga, Japan's Chief Cabinet Secretary and a longtime loyal assistant of outgoing Prime Minister Shinzo Abe, has emerged as a favourite to succeed him in an upcoming internal party vote https://t.co/n1zNdzRRgy
— The Sydney Morning Herald (@smh) September 2, 2020
David Walton and Akimoto Daisuke: The decision by the Turnbull government in 2016 to select a French company to produce Australia’s next generation of submarines over Japan’s tender highlighted the limitations of networks and friendships.https://t.co/HRpQaOGhts
— The Lowy Institute (@LowyInstitute) September 4, 2020
"With Australia seeking ever-closer regional cooperation with Japan these days, it will be interesting to see whether the country’s investors will be unnerved by being caught in Australia’s trade row with China."@Greg__Earl writes for The Interpreter.https://t.co/NWqOT8rfcL
— The Lowy Institute (@LowyInstitute) August 31, 2020
Abe aimed to move mountains, setting Japan high goals for the future | Purnendra Jain https://t.co/vynrzxabC2
— The Lowy Institute (@LowyInstitute) August 30, 2020
With the Indo-Pacific increasingly a battleground for technological competition, it appears likely that US-China tensions will complicate Japan-ASEAN digital ties.
Elliot Silverberg and Patrick Madaj write for The Interpreter.https://t.co/lKvF8wR7P4
— The Lowy Institute (@LowyInstitute) August 16, 2020
"In a similar address to the Lowy Institute a year ago, @ScottMorrisonMP also praised India and Japan as countries with 'shared values' to Australia."@ConversationEDUhttps://t.co/iARwXSrBzA
— The Lowy Institute (@LowyInstitute) August 6, 2020
"In a commentary last year written for The Interpreter blog from Australia's Lowy Institute, Layton detailed just how far the Chinese flights stretch the JASDF, and how China has the resources to push Japan to limits it may not be able to reach."@cnnihttps://t.co/LnI3HSyOxu
— The Lowy Institute (@LowyInstitute) July 30, 2020
"An overwhelming 82 per cent of Australians said they expected Japan to act responsibly in the world. On the same question, the response regarding China was a dismal 23 per cent"
Nonresident Fellow @Rory_Medcalf on Lowy Institute Poll in @FinancialReviewhttps://t.co/0dAWDLfKCd
— The Lowy Institute (@LowyInstitute) July 13, 2020
Beyond Covid, the chance for a broader Australia-Japan relationship | Donna Weeks https://t.co/jWd4qbeuwC
— The Lowy Institute (@LowyInstitute) July 6, 2020
As China rises, does Australia, India, Japan, and the United States have any real prospect of rebalancing relationships in Asia?
Read the latest Lowy Institute Analysis on the Security Quadrilateral Dialogue by Dr Lavina Lee. https://t.co/3rHK0bjip3
— The Lowy Institute (@LowyInstitute) May 22, 2020
Japan: Article 9 conundrum rears its head again | David Walton https://t.co/g3erhFcktW
— The Lowy Institute (@LowyInstitute) February 24, 2020
Japan–South Korea tensions show little sign of easing | Kate Kalinova https://t.co/a5lWZFyghy
— The Lowy Institute (@LowyInstitute) February 17, 2020
#BREAKING Japanese Coastguard has reportedly made the decision to suspend its fulltime search for the 40 people still missing from the livestock ship. https://t.co/5kPFsNszQP pic.twitter.com/v3KPgjWKNA
— nzherald (@nzherald) September 10, 2020
#BREAKING Missing Kiwis: Japan to resume search for crew of livestock ship https://t.co/tAqQjJTgcc pic.twitter.com/YtKCeBkt2z
— nzherald (@nzherald) September 7, 2020
#BREAKING The second person rescued by Japanese coastguard has died. https://t.co/YrzrVGD9Sg pic.twitter.com/G3vTOgyyKc
— nzherald (@nzherald) September 4, 2020
#BREAKING They sent a distress signal at 4.45am NZT off the coast of Japan as the area was hit by a Typhoon. Now the ship has disappeared. https://t.co/UJUmRTrPFY pic.twitter.com/KGDrbXTWTJ
— nzherald (@nzherald) September 2, 2020
Japan's Parliament has elected Yoshihide Suga as prime minister, replacing long-serving leader Shinzo Abe with his right-hand man. https://t.co/i4yQL9llz4
— CBC News (@CBCNews) September 16, 2020
Yoshihide Suga has been elected as the new head of Japan's ruling party, virtually guaranteeing that he will become the country's next prime minister. https://t.co/rqR2DwTZGn
— CBC News (@CBCNews) September 14, 2020
One person in Japan is dead, and at least two are missing in South Korea after a powerful typhoon. https://t.co/f8sxEEjNOw
— CBC News (@CBCNews) September 8, 2020
U.S. authorities have arrested a former Green Beret and his son who are accused of using large boxes to help scurry Nissan chairman Carlos Ghosn out of Japan. https://t.co/UPxjNx3A05
— CBC News (@CBCNews) May 20, 2020
As the coronavirus spreads in Japan, the chief executive of the Tokyo Games said Friday he can't guarantee the postponed Olympics will be staged next year — even with the long delay. https://t.co/V6QqzigJwC
— CBC News (@CBCNews) April 10, 2020
Japan's prime minister says he will declare a state of emergency for seven prefectures, with Japan also launching its largest ever stimulus package. https://t.co/f6SWfrhyQg
— CBC News (@CBCNews) April 7, 2020
The streets of Tokyo remain busy as Japan adopts its own approach to preventing the spread of coronavirus, one that relies on tracing cases and requesting cooperation, not lockdowns. https://t.co/YKNNsYkV4N @sasapetricic
— CBC News (@CBCNews) April 4, 2020
Japan Olympic minister Seiko Hashimoto says the Tokyo Summer Games could be held later in 2020 due to fast-spreading COVID-19. https://t.co/8gEqMSG8cX
— CBC News (@CBCNews) March 3, 2020
Canadian quarantined in Japan with asymptomatic COVID-19 describes comforts during enforced stay. https://t.co/HfOuAh3Jhb pic.twitter.com/y70dRyVzIE
— CBC News (@CBCNews) February 27, 2020
Japan’s Yoshihide Suga poised to win party race, succeed Shinzo Abe as PM https://t.co/XHP4temuFe
— The Globe and Mail (@globeandmail) September 14, 2020
Japan, eyeing Olympics, lines up half-billion doses of COVID-19 vaccine https://t.co/N3ShUXL25O
— The Globe and Mail (@globeandmail) August 28, 2020
Japan says China has used coronavirus to expand territory, influence https://t.co/6vtuc3NY8T
— The Globe and Mail (@globeandmail) July 14, 2020
Japan to end Tokyo’s state of emergency, eyes massive new stimulus https://t.co/2xqo1lBlOs pic.twitter.com/SQsnCVxqFx
— The Globe and Mail (@globeandmail) May 25, 2020
Japan’s Shinzo Abe slammed over ‘stay home’ shutdown tweet https://t.co/ZpaFBQxGOg pic.twitter.com/93TI0ssMk1
— The Globe and Mail (@globeandmail) April 13, 2020
Nearly 40 feared dead as torrential rains continue to ravage southwest Japan https://t.co/6f7TjQpdH8 pic.twitter.com/DRfb2d0pvW
— The Globe and Mail (@globeandmail) July 6, 2020
Japan bracing for dangerously powerful Typhoon Haishen https://t.co/6iorZ3r31N
— The Globe and Mail (@globeandmail) September 4, 2020
Japan’s ruling party urges government to cancel Xi’s visit over new Hong Kong national security law https://t.co/CVKC12xKeB pic.twitter.com/g0Ybpfpp4g
— The Globe and Mail (@globeandmail) July 7, 2020
Japan ignored the usual rules but contained COVID-19. How did it work? https://t.co/dDDSjdHmbe
— National Post (@nationalpost) May 25, 2020
#Breaking: Olympic Games delayed one year after agreement reached with IOC and Japan PM. https://t.co/5AIrozWunM
— Toronto Star (@TorontoStar) March 24, 2020
Articles about Japan after Prime Minister’s resignation announcement through today 首相辞意表明後今日までの日本関連英文記事
All the below tweets are in English.
標記につき取り急ぎ貼っておきます。
Japan's Suga says coronavirus a top priority, to stay on Abe policy course https://t.co/KH014DRWAv pic.twitter.com/4qduiKwGMc
— Reuters (@Reuters) September 8, 2020
Japan to spend $6.3 billion from emergency reserve for coronavirus vaccines https://t.co/FQOL8jfScS pic.twitter.com/d0szcvoMhm
— Reuters (@Reuters) September 8, 2020
Japan's Suga signals chance of calling snap election: Asahi https://t.co/FNnJVT5bRf pic.twitter.com/HysayXM3Fx
— Reuters (@Reuters) September 8, 2020
Senior Japan ruling party member suggests early election: media https://t.co/VWOXatSa1Q pic.twitter.com/c2pMrevZLd
— Reuters (@Reuters) September 6, 2020
Japan's Suga jumps in popularity, tops favourability poll for next PM https://t.co/GrPwSAlYxI pic.twitter.com/qpyQBhiAhV
— Reuters (@Reuters) September 4, 2020
Backroom deals, old-school politics help rise of Japan's likely new premier https://t.co/vmEpeiK4uo pic.twitter.com/kgPBXJYtJZ
— Reuters (@Reuters) September 3, 2020
Japan defence chief Kono expects to be prime minister one day, but backs Suga to succeed Abe https://t.co/DD2zcP0akQ pic.twitter.com/UtWRxXKs1T
— Reuters (@Reuters) September 3, 2020
Japan’s Chief Cabinet Secretary Yoshihide Suga has officially declared he will run for the leadership of the ruling party, making him the top contender to take over from Prime Minister Shinzo Abe https://t.co/TzpKpHbjBC pic.twitter.com/jORgubKuHm
— Reuters (@Reuters) September 3, 2020
Factbox: A stern enforcer who does 100 sit-ups daily – some facts about Japan's Suga https://t.co/pcTXr9DwNM pic.twitter.com/jEb9W3UV5k
— Reuters (@Reuters) September 3, 2020
UK/Japan trade deal good for consumers, companies, Johnson tells Abe https://t.co/TNjnqVIUQH pic.twitter.com/WXRIUdjXun
— Reuters (@Reuters) September 2, 2020
Japan's Suga says to brief on party leadership race, in signal he intends to run https://t.co/6WRex12uln pic.twitter.com/5bClAPgbrY
— Reuters (@Reuters) September 2, 2020
Suga as Japan's next premier may be tough partner for Bank of Japan https://t.co/sdxZ95GQMq pic.twitter.com/Gqtqh5tZnj
— Reuters (@Reuters) September 2, 2020
Japan's Suga expected to announce candidacy for PM race https://t.co/73AeSksV6K pic.twitter.com/krK0Mmsae7
— Reuters (@Reuters) September 2, 2020
Yoshihide Suga, a long-time lieutenant of outgoing Japanese Prime Minister Shinzo Abe is seen as a top contender in the PM race after he won the backing of the ruling party's largest faction https://t.co/Hgl9w7shZi pic.twitter.com/eyRQRDo5Jx
— Reuters (@Reuters) September 1, 2020
Japan's next premier to find pandemic eroding job market gains made by 'Abenomics' https://t.co/0L8X5in763 pic.twitter.com/gNn0nIHzzi
— Reuters (@Reuters) September 1, 2020
Suga seen top contender in Japan PM race as ruling party plans slimmed-down vote https://t.co/wVg1hKtAud pic.twitter.com/IXQ4q2lUwz
— Reuters (@Reuters) September 1, 2020
Japan former foreign minister Kishida announces candidacy to succeed PM Abe https://t.co/KAJ37IIfMb pic.twitter.com/qMr56YBcHi
— Reuters (@Reuters) September 1, 2020
Japan's Motegi: to decide whether to run in party leadership race in a day https://t.co/8lZGGf2BoK pic.twitter.com/o5VXzZLFuc
— Reuters (@Reuters) September 1, 2020
Yoshihide Suga, Japan’s chief cabinet secretary and a long-time lieutenant of outgoing Prime Minister Shinzo Abe, won the backing of the largest faction of the ruling party to become its next leader, according to public broadcaster NHK https://t.co/CLTrfpHfLq pic.twitter.com/vwmsuBxYPr
— Reuters (@Reuters) September 1, 2020
Japan LDP execs agree on simplified format to pick next PM: Nikai https://t.co/JBSiprHkGl pic.twitter.com/MKUrzwGUYf
— Reuters (@Reuters) September 1, 2020
Japan Defence Minister Kono says still undecided on run for ruling party leadership https://t.co/RIOCsS4eR8 pic.twitter.com/mL7SYNzqWs
— Reuters (@Reuters) September 1, 2020
Ex-Japan defence chief mum on whether he'll join PM race https://t.co/xL8Vv4OMDZ pic.twitter.com/UJZnho5erd
— Reuters (@Reuters) August 31, 2020
How does Abenomics stack up? Reuters asked the experts https://t.co/rk2GIdauOE pic.twitter.com/7uwEQXu575
— Reuters (@Reuters) August 31, 2020
Japan's ruling party to hold September 14 leadership vote; four possible candidates for PM https://t.co/vnOX7Hld4q pic.twitter.com/OyLahCgjeL
— Reuters (@Reuters) August 31, 2020
Japan's PM candidate Kishida cautious about cutting sales tax https://t.co/NX1GzOZzii pic.twitter.com/MF5DaqtiwV
— Reuters (@Reuters) August 31, 2020
Ex-defence minister Ishiba is people's choice for next Japan PM: polls https://t.co/vz2wwRC27L pic.twitter.com/FDUz78EpgK
— Reuters (@Reuters) August 31, 2020
In his first race for office, Japan's likely next prime minister knocked on 30,000 doors and wore out six pairs of shoes https://t.co/9u4C78fBxC
— The Wall Street Journal (@WSJ) September 7, 2020
By the time Prime Minister Shinzo Abe announced his resignation last week, he had presided over a remarkable and unexpected opening up of Japan to the world https://t.co/Q8QCHMDkLk
— The Wall Street Journal (@WSJ) September 3, 2020
Japan’s next leader will face a question many other countries are now grappling with because of the coronavirus pandemic: How much can central banks do to pull economies out of a deep malaise? https://t.co/ijydChWQXa
— The Wall Street Journal (@WSJ) August 31, 2020
Prime Minister Shinzo Abe’s two stints in office reshaped modern Japan https://t.co/VQbZJ35bZD
— The Wall Street Journal (@WSJ) August 29, 2020
Whoever Japan's Liberal Democratic Party elects as its leader, probably within the next week, will almost certainly become the country's next prime minister. But it isn’t clear who that will be. https://t.co/1vYWIME0Wb
— The New York Times (@nytimes) August 30, 2020
News Analysis: Whoever Japan's next leader is will have to face the coronavirus, a tanking economy, an aggressive China, a postponed Olympics and a U.S. election. And that's just the start. https://t.co/dHglv1aM1b
— The New York Times (@nytimes) August 30, 2020
Japan’s "Mr. Fixit," Yoshihide Suga, set to succeed Shinzo Abe as leader https://t.co/HaoZIM3NBs
— The Washington Post (@washingtonpost) September 1, 2020
Opinion: Shinzo Abe decided to go all out on Donald Trump. He’s probably regretting it now. https://t.co/u2VEjVoz9D
— The Washington Post (@washingtonpost) August 30, 2020
What does #Abe Shinzo’s resignation mean for Japan’s future? The post-Abe calculus is aggravated by Japan’s domestic political flux, a congested electoral calendar and unpromising economic and geopolitical environments, writes @RobertAlanWard | https://t.co/EelZfg6zG6 pic.twitter.com/5RHLVs3odh
— IISS News (@IISS_org) August 28, 2020
'The old paradigm of the US-Japan alliance is that Japan wears the "shield" and hosts the "sword". But that paradigm has been breaking down for many years,' says @graham_euan, Senior Fellow for Asia-Pacific Security | @firstpost https://t.co/56fnzqDI3B
— IISS News (@IISS_org) August 17, 2020
China’s rise as a geo-economic power has driven the Abe administration to reshape its foreign-policy bureaucracy and recalibrate its approach to economic statecraft – read more in the Strategic Comment | https://t.co/eVGsEQOXkB pic.twitter.com/3U0FLlthPA
— IISS News (@IISS_org) August 24, 2020
'Chinese activities in the waters around the Senkaku/Diaoyu islands have undergone a significant change over the past few months. This is a potentially dangerous development for Sino–Japanese relations.'
New Newsbrief from Dr Alessio Patalano.https://t.co/8ysPOtONLs pic.twitter.com/T0MwNK9M0h— RUSI (@RUSI_org) August 22, 2020
https://twitter.com/rielcano/status/1297115296977817602
“China has a lot of cards to play, so the policies of the next administration—again, regardless of who is president—will have to respond to Beijing.”
Insights from @JJCarafano on the future of Asia policy via @jljzen: https://t.co/Pqn3BYeD0F
— Heritage Foundation (@Heritage) August 21, 2020
Yoshihide Suga, Japan's Chief Cabinet Secretary and a longtime loyal assistant of outgoing Prime Minister Shinzo Abe, has emerged as a favourite to succeed him in an upcoming internal party vote https://t.co/n1zNdzRRgy
— The Sydney Morning Herald (@smh) September 2, 2020
Japan's Prime Minister Shinzo Abe has been forced to resign due to ongoing poor health.https://t.co/OmmN6lmxpi
— nzherald (@nzherald) August 28, 2020
Five venerable Japanese companies were sitting in the bargain bin in plain sight. It took a 90-year-old Warren Buffett to scoop them up. https://t.co/LmocOAatM2
— The Wall Street Journal (@WSJ) September 5, 2020
Japanese conglomerate SoftBank fueled the recent stock market rally by buying options tied to billions of dollars worth of individual tech stocks, people familiar with the matter say https://t.co/5qJeeaemXS
— The Wall Street Journal (@WSJ) September 4, 2020
SoftBank value slumps as investors fear it may be the 'Nasdaq whale' https://t.co/TY75uJPCcI
— The Guardian (@guardian) September 7, 2020
Warren Buffett’s Berkshire Hathaway took stakes in five Japanese trading companies, expanding its reach abroad https://t.co/QJkPjn15ou pic.twitter.com/Dsc5vFQlUO
— Stuart Wallace (@StuartLWallace) August 31, 2020
BREAKING: Warren Buffett's Berkshire Hathaway buys stakes in Japan's five leading trading companies https://t.co/9RzX6prgmH
— CNBC Now (@CNBCnow) August 30, 2020
https://twitter.com/Forbes_MENA_/status/1300379518184689664
Berkshire Hathaway invests $6 billion in five Japanese companies https://t.co/GPzyETMsvI pic.twitter.com/JWGLP2GK5D
— New York Post (@nypost) August 31, 2020
The Japanese Coast Guard was searching for a livestock ship that capsized with dozens of crew members and nearly 6,000 cows aboard, after a typhoon barreled through East Asia on Thursday https://t.co/49zbjiV6Nx
— The New York Times (@nytimes) September 3, 2020
Japan's convenience store industry is under scrutiny after allegations that companies used strong-arm tactics to force franchisees to maintain 24-7 operations, leading overworked owners to collapse from exhaustion https://t.co/Jw6JgV5NZo
— The New York Times (@nytimes) September 3, 2020
Naomi Osaka brought seven face masks to the U.S. Open, each one honoring a victim of violence https://t.co/R8DtfLqODc
— The Washington Post (@washingtonpost) September 1, 2020
Japan coastguard finds second person in search for crew of capsized cattle ship https://t.co/jIvgQsXsbt
— The Guardian (@guardian) September 4, 2020
Typhoon Maysak: ship with 43 crew and nearly 6,000 cattle missing off Japan https://t.co/gU83kN9HXq
— The Guardian (@guardian) September 3, 2020
#BREAKING The second person rescued by Japanese coastguard has died. https://t.co/YrzrVGD9Sg pic.twitter.com/G3vTOgyyKc
— nzherald (@nzherald) September 4, 2020
Japan's Sumitomo sells all of its stake in U.S. Marcellus shale gas project https://t.co/LggosGUiNQ pic.twitter.com/CvYxUJ9YpS
— Reuters (@Reuters) September 8, 2020
Japan's economy sank deeper into its worst post-war contraction in the second quarter as the coronavirus jolted businesses, intensifying the challenge for the country's new leader https://t.co/eeC1TtV3Ku pic.twitter.com/72RDS5h49f
— Reuters (@Reuters) September 8, 2020
Japan real wages decline for fifth month in July as pandemic woes persist https://t.co/ujb8GDH0nK pic.twitter.com/TjeIxXD0hp
— Reuters (@Reuters) September 8, 2020
Japan's July household spending falls 7.6% year-on-year https://t.co/05HkfoDhDx pic.twitter.com/ncXaEsJqIB
— Reuters (@Reuters) September 8, 2020
Japan's Nishimura says rising income to underpin consumption https://t.co/5qJ2SSC5jr pic.twitter.com/1zwxo0quDi
— Reuters (@Reuters) September 8, 2020
Japan's second-quarter GDP revised down to annualised 28.1% contraction https://t.co/ciKbcDVRdG pic.twitter.com/sM3nX7nGwH
— Reuters (@Reuters) September 8, 2020
Japan real wages decline for fifth month in July as pandemic woes persist https://t.co/oLovkMNqCE pic.twitter.com/2mRvUgLL4R
— Reuters (@Reuters) September 8, 2020
Japan says it offered Mauritius 'unprecedented' support, including financial https://t.co/cDucu3Tijm pic.twitter.com/rcaUDTSeb5
— Reuters (@Reuters) September 7, 2020
Renault to develop, build next-generation Nissan Micra: report https://t.co/IIW1D4HZMe pic.twitter.com/w1AmP2J46G
— Reuters (@Reuters) September 7, 2020
The Fed’s landmark shift to a more tolerant stance on inflation will be a drag on the dollar for years and will raise hard questions about the role of central banking, challenging policymakers from Frankfurt to Tokyo https://t.co/PzzcVF2WEa pic.twitter.com/bwU58rbiqg
— Reuters (@Reuters) September 7, 2020
Japanese government exposed to 40% of $6.7 billion Nissan loans: sources https://t.co/s74k5ibgXO pic.twitter.com/3TL6RnDHc1
— Reuters (@Reuters) September 7, 2020
Death knell sounds for some of Japan's oldest department stores https://t.co/XkVMHEJQop pic.twitter.com/r2UTHa6EXI
— Reuters (@Reuters) September 7, 2020
Amazon Japan submits improvement plan to regulators: Asahi https://t.co/FchYZNr0i7 pic.twitter.com/lhstyjzaMm
— Reuters (@Reuters) September 4, 2020
Japan's government is considering further assistance to help Mauritius deal with a major oil spill after a Japanese-owned boat struck a coral reef pic.twitter.com/LELPYdmqgR
— Reuters (@Reuters) September 3, 2020
Japan's coastguard rescued one person while searching for a cargo ship carrying nearly 6,000 cattle and dozens of crew members that went missing in the East China Sea https://t.co/An8nLUfi4a pic.twitter.com/KZekO8cFJi
— Reuters (@Reuters) September 3, 2020
BOJ's Kataoka urges bolder easing to battle deflation risk https://t.co/2LxzPSU2SE pic.twitter.com/UWB9FJqFg5
— Reuters (@Reuters) September 3, 2020
Japan's August service sector activity worsens as pandemic stymies recovery https://t.co/wHHpqn8nBN pic.twitter.com/maiuZJwI0y
— Reuters (@Reuters) September 3, 2020
Japan looks to AI as coronavirus challenges go-and-see quality control mantra https://t.co/INQIGWyG16 pic.twitter.com/4oSruhvBft
— Reuters (@Reuters) August 31, 2020
As fintech upends banking, Japan regulator expects more cross-boundary tie-ups https://t.co/nhVjPT8MC3 pic.twitter.com/WlsEaJuhsB
— Reuters (@Reuters) August 31, 2020
Japan July retail sales fall 2.8% year-on-year, government data shows https://t.co/HlH0tdU2Sr pic.twitter.com/3bQ5tUxewH
— Reuters (@Reuters) August 31, 2020
From @Breakingviews: @johnsfoley explains why Warren Buffet is going big in Japan pic.twitter.com/tA2jBVqc13
— Reuters (@Reuters) September 1, 2020
Nippon Steel to seek overseas M&As, but not in Japan: president https://t.co/lKCoLkWAui pic.twitter.com/xgb2PQVlu1
— Reuters (@Reuters) September 1, 2020
Warren Buffett looks to Japan, takes 5% stakes in five biggest trading firms https://t.co/CErrl7nR2E pic.twitter.com/3wA9AUhtS8
— Reuters (@Reuters) August 31, 2020
Japanese PM Shinzo Abe says he's stepping down because of a chronic health problem https://t.co/0p5wm1yElD
— POLITICO (@politico) August 29, 2020
Japanese Prime Minister Shinzo Abe has expressed his intention to step down, citing his declining health, according to Japan’s NHK television and other media https://t.co/0p5wm1yElD
— POLITICO (@politico) August 28, 2020
Prime Minister Abe’s Resignation Announcement 安倍首相辞意表明
All the below tweets are in English.
日本時間29日午後2時までに見つけたツイートを取り急ぎ以下貼っておきます。
Shinzo Abe has announced his resignation citing health concerns.
How will his time as Japan's Prime Minister be remembered?
Read more: https://t.co/VK2X9gdljG pic.twitter.com/Yco7hllbPG
— CNN International (@cnni) August 28, 2020
Shinzo Abe has announced his resignation citing health concerns.
How will his time as Japan's Prime Minister be remembered?
Read more: https://t.co/VK2X9gdljG pic.twitter.com/3vdv68HLct
— CNN International (@cnni) August 28, 2020
Japan's longest serving Prime Minister, Shinzo Abe, had bold ideas to build a stronger, more prosperous & confident nation. COVID-19 turned what was to be his banner year into a major disappointment. Abe steps down amid plummeting approval ratings for his pandemic leadership. pic.twitter.com/Iu7Od3WMyZ
— Will Ripley (@willripleyCNN) August 28, 2020
#BREAKING: Japan's Prime Minister Shinzo Abe resigns for health reasons. @willripleyCNN reports pic.twitter.com/H1hJNSHMrB
— CNN Early Start (@EarlyStart) August 28, 2020
Japan's Prime Minister Shinzo Abe holds a news conference https://t.co/r2ACTyT1ku
— Reuters (@Reuters) August 28, 2020
BREAKING: Japanese prime minister Shinzo Abe has resigned due to ill health.
Sky News' @chesh says it's a "big moment" for Japanese politics and it has come as a "shock" announcement during the pandemic.
More on this story here: https://t.co/DZBxRkg0dh pic.twitter.com/KoxE9ZlS5q
— SkyNews (@SkyNews) August 28, 2020
https://twitter.com/QuickTake/status/1299266444786507778
VIDEO: "I have decided to step down from the post of the prime minister!"
Japan's Prime Minister Shinzo Abe announces he will resign over health problems, in a development that kicks off a leadership contest in the world's third-largest economy pic.twitter.com/OLlI85Dzf1— AFP news agency (@AFP) August 28, 2020
PM #Abe steps down citing health reasons pic.twitter.com/LLIoHCIXo2
— Ruptly (@Ruptly) August 28, 2020
BREAKING: Japan's PM Shinzo Abe resigns for health reasons.
Read more: https://t.co/fZ98KQeHXA https://t.co/nOR5NgLBYF
— Al Jazeera News (@AJENews) August 28, 2020
Japanese Prime Minister Shinzo Abe is set to resign, according to national broadcaster NHK.#Japan #Abehttps://t.co/i2GV2XWTtE
— Al Arabiya English (@AlArabiya_Eng) August 28, 2020
Japan's longest serving prime minister Shinzo Abe is resigning due to health reasons. The news revives memories of when he came to West Palm Beach to talk trade with President Trump.
Read more: https://t.co/yA2ru00Phr pic.twitter.com/xGPmVam9Lh— WPEC CBS12 News (@CBS12) August 28, 2020
Wow. The mark of a true leader. Japanese Prime Minister Shinzo Abe resigns after being truthful about the state of his health. pic.twitter.com/jSaHiW1EuF
— Karen Davila (@iamkarendavila) August 28, 2020
#Gravitas | As Japan's Prime Minister, @AbeShinzo invested significant diplomatic capital in developing strong ties with India. @palkisu brings you the story of Abe's relationship with India. pic.twitter.com/x4a5SeP00w
— WION (@WIONews) August 28, 2020
India and Japan relation further strengthened under PM Abe’s leadership.
Wish you a speedy recovery, Sir. https://t.co/7qXzMNmf5q
— Tejasvi Surya (@Tejasvi_Surya) August 28, 2020
Abe to hold phone talks with Trump https://t.co/ML3LNJ7BrT
— NHK WORLD News (@NHKWORLD_News) August 29, 2020
Under an umbrella, Pres Trump descends the steps of Air Force One as lightning strikes in the distance. On the flight back from NH, he told reporters he feels "very badly" about Japanese PM Shinzo Abe stepping down. "I'm just paying my highest respect," he said. pic.twitter.com/MRUfDyeFXj
— Mark Knoller (@markknoller) August 29, 2020
How unusual was Abe’s leadership stability? This @Reuters graphic illustrates it well. pic.twitter.com/UaA9vYEHz7
— Alastair Gale (@AlastairGale) August 28, 2020
Australia is thankful for the true friend we have had in Shinzo Abe as Prime Minister of Japan. His leadership, wisdom, generosity and vision have championed the cause of peace, freedom and prosperity in our region and the world more broadly. pic.twitter.com/GCdRo371ru
— Scott Morrison (@ScottMorrisonMP) August 28, 2020
This is why the world will miss Shinzo Abe https://t.co/ioJlGbSpQD
— Malcolm Turnbull (@TurnbullMalcolm) August 28, 2020
Under Shinzo Abe, Japan spoke with strength and consistency. He hasn’t just been the longest serving Japanese prime minister, he has been one of the very best. The free trade deal epitomised his commitment to liberal values as well as his regard for Australia. pic.twitter.com/3Ds463xuEW
— Tony Abbott (@HonTonyAbbott) August 28, 2020
.@AbeShinzo has achieved great things as PM of Japan – for his country and the world. Under his stewardship the UK-Japan relationship has gone from strength to strength in trade, defence and our cultural links. Thank you for all your years of service and I wish you good health.
— Boris Johnson (@BorisJohnson) August 28, 2020
“@AbeShinzo – your vision, your leadership, and your friendship have brought our two countries closer. For that and for all the years you’ve dedicated to building a better world, thank you. Wishing you good health, my friend.” – Prime Minister Justin Trudeau
— CanadianPM (@CanadianPM) August 28, 2020
Angela Merkel ‘regrets’ Shinzo Abe’s resignation, wishes him best for his health https://t.co/RNSh1U64Gk
— Republic (@republic) August 28, 2020
"We've had a great relationship and I just feel very badly about it," said US President Donald Trump
Read more: https://t.co/vUD3w8CTcd#USPresident #DonaldTrump #Japan #ShinzoAbe #PrimeMinisterAbe #Opoyi
— Opoyi (@Opoyis) August 29, 2020
I am grateful for your friendship and leadership, @AbeShinzo. I’m sad to see you step down, but I know the strong alliance between our countries and peoples will continue for generations to come. Wishing you good health in the years ahead, my friend. pic.twitter.com/M0cMT5y9Dd
— Joe Biden (@JoeBiden) August 28, 2020
It may not be long before the Abe era is mourned by those at home and its allies abroad, Michael Auslin writes.https://t.co/1A76azxpGy
— Foreign Policy (@ForeignPolicy) August 29, 2020
Shinzo Abe may not be popular—but he was successful, William Sposato writes.https://t.co/sdIfOD9kDR
— Foreign Policy (@ForeignPolicy) August 28, 2020
Japanese Prime Minister Shinzo Abe announced he was stepping down on Friday, citing health issues https://t.co/moOKfPbU2i
— TIME (@TIME) August 28, 2020
Japan's Abe Shinzo resigns over ulcerative colitis problems, a condition he has suffered with for decades https://t.co/bNyNjQtUGL
— Newsweek (@Newsweek) August 28, 2020
Shinzo Abe, Japan’s longest-serving Prime Minister, is resigning for the second time—and one year before his term is set to end—due to chronic health issues https://t.co/0ISBK4bdeZ pic.twitter.com/BcTrExMndI
— Forbes (@Forbes) August 28, 2020
Abe is expected to stay on until a new party leader is elected and formally approved by the parliament. https://t.co/8mWy01woM7
— HuffPost (@HuffPost) August 29, 2020
Japanese Prime Minister Shinzo Abe to resign due to deteriorating health https://t.co/XUvxy9D7F8
— CBS News (@CBSNews) August 28, 2020
Shinzo Abe announced plans on Friday to cut short his stint as Japan's prime minister, citing ill health — but the legacy of his economic policies will endure for decades | Analysis https://t.co/K21LECuiyu
— CNN International (@cnni) August 28, 2020
Japanese Prime Minister Shinzo Abe has battled ulcerative colitis for years and two recent hospital visits within a week had fanned questions on whether he could stay in the job until the end of his term as ruling party leader. https://t.co/GGNBfmWV4p pic.twitter.com/hS57uIbU25
— Inquirer (@inquirerdotnet) August 28, 2020
Hudson Institute thanks Prime Minister @AbeShinzo for his longstanding efforts to deepen the Japan-US relationship, and for his personal friendship to Hudson. Under PM Abe’s leadership, Japan achieved great success in those objectives. Our statement: https://t.co/B0CK9vZ5K1 pic.twitter.com/ggcgJwZPMa
— Hudson Institute (@HudsonInstitute) August 28, 2020
"Shinzo Abe’s Decision to Step Down" – Read the Latest Critical Questions Post from the Japan Chair: https://t.co/8iCIGMKplp
— CSIS Japan Chair (@JapanChair) August 28, 2020
PODCAST: What’s next for Japan after Prime Minister Shinzo Abe’s surprise resignation? @solis_msolis discusses on @policypodcasts' The Current. Listen: https://t.co/rvCgJFr0M1
— Brookings FP (@BrookingsFP) August 28, 2020
.@AsiaProgram's @GotoEastAsia and @AbeDenmark react to the news that Japan's Prime Minister Shinzo Abe will resign: https://t.co/dNIf8ym0vF
— The Wilson Center (@TheWilsonCenter) August 29, 2020
Japan PM Abe says he's stepping down because a chronic illness has resurfaced, says, "It is gut wrenching to have to leave my job before accomplishing my goals." https://t.co/inwWiHDn0p
— The Associated Press (@AP) August 28, 2020
BREAKING: Japanese Prime Minister Shinzo Abe will step down as the country’s leader due to chronic health issues, he announced at a press conference Friday. https://t.co/2SzCKPoB8y
— ABC News (@ABC) August 28, 2020
As Prime Minister Shinzo Abe steps down, the score card for his growth policy is marked by gains in driving the world’s third-largest economy, and by missed targets and unresolved challenges https://t.co/0JDhvU98Ej
— The Wall Street Journal (@WSJ) August 28, 2020
Ulcerative colitis, the malady that has forced Prime Minister Shinzo Abe of Japan to resign, is a chronic inflammation of the large intestine that can recur unpredictably, even with treatment. https://t.co/03xB2upq4U
— New York Times World (@nytimesworld) August 28, 2020
Shinzo Abe, Japan’s longest-serving prime minister, announced that he would resign because of ailing health.
Here is a look at his time in office and his legacy. https://t.co/2XSkiKFIoy
— The New York Times (@nytimes) August 28, 2020
PM Abe’s resignation has potentially major consequences for the U.S. Japan is central to our efforts to limit China’s push for power in the Indo-Pacific. Will Abe’s successor remain as stalwart? via @NYTimes https://t.co/KzgEY8et0n
— Nicholas Burns (@RNicholasBurns) August 28, 2020
Japanese Prime Minister Shinzo Abe resigns, citing health reasons https://t.co/OJ3eL63I1O
— The Washington Post (@washingtonpost) August 28, 2020
Shinzo Abe, Japan’s Longest-Serving Prime Minister, Announces His Resignation https://t.co/mmIVhZBgIH
— Daily Caller (@DailyCaller) August 28, 2020
NEW: Japan’s longest-serving prime minister, Shinzo Abe, said Friday he intends to step down because a chronic health problem has resurfaced. He told reporters that it was “gut wrenching” to leave so many of his goals unfinished. https://t.co/vPiYcfeSuW
— Toronto Star (@TorontoStar) August 28, 2020
Japan's Shinzo Abe steps down as PM due to health concerns https://t.co/JW9msLGzhg
— The Vancouver Sun (@VancouverSun) August 28, 2020
Shinzo Abe: Revisionist nationalist or pragmatic realist? https://t.co/nD4xwEXjMu
— BBC News (World) (@BBCWorld) August 28, 2020
Japan's longest-serving prime minister, Shinzo Abe has resigned for health reasons
He was known for his hawkish policies and his signature economic strategy of "Abenomics"https://t.co/dnJoiJhmM0
— BBC News (World) (@BBCWorld) August 28, 2020
Japanese stocks slump and yen rises after Shinzo Abe resignation report – business live https://t.co/ZTFqZi32AD
— The Guardian (@guardian) August 28, 2020
Shinzo Abe resigns as Japanese prime minister due to ill-health – video https://t.co/Ju3eAeXlc2
— The Guardian (@guardian) August 28, 2020
Japan's Prime Minister Shinzo Abe is to resign over health problems, top lawmakers said Friday, in a bombshell development will end a record-setting tenure with no clear successor in yet in place
— The Telegraph (@Telegraph) August 28, 2020
As Shinzo Abe quits, he will be remembered more as a caretaker PM than a radical reformer, writes David McNeill in Nagano (via @irishtimesworld)https://t.co/oEtkjo2F0e
— Irish Times World (@IrishTimesWorld) August 28, 2020
► VIDEO: "I really struggled to make this decision", Japanese PM Shinzo Abe steps down over health issues https://t.co/muandD55fn pic.twitter.com/BMAdyoxdWy
— Irish Times Video (@irishtimesvideo) August 28, 2020
Japanese PM Shinzo Abe to resign amid health concerns – report https://t.co/szeWoqd4Iv pic.twitter.com/Bv2xhLKGPM
— Independent.ie (@Independent_ie) August 28, 2020
Shinzo Abe, Japan’s longest-serving prime minister, says he is resigning because a chronic illness has resurfaced https://t.co/qx8HnPqJQC
— Irish Examiner (@irishexaminer) August 28, 2020
Speculation about his health increased in recent days after he made two separate trips to hospital for unspecified medical checks https://t.co/yQVTcY9gC6
— RTÉ News (@rtenews) August 28, 2020
▶️ Japan: Shinzo Abe quits over health problems https://t.co/Hyr8PbsNvx pic.twitter.com/d1144Rb93f
— FRANCE 24 English (@France24_en) August 28, 2020
Japanese Prime Minister Shinzo Abe is set to resign over health issues.https://t.co/zBzrUSbsnZ
— DW News (@dwnews) August 28, 2020
Without a clear front-runner to succeed him, speculation has persisted that the outgoing Japanese prime minister is eyeing a fourth term.
But Prime Minister Shinzo Abe has now singled out four of his loyal deputies as potential successors.https://t.co/QEkN0k9RgC
— Nikkei Asian Review (@NAR) August 28, 2020
https://twitter.com/Noahpinion/status/1299489049753739265
The yen rallied 1% versus the dollar following Prime Minister Shinzo Abe’s plans to resign due to ill-health https://t.co/fMvD7nwA6F
— Bloomberg (@business) August 28, 2020
https://twitter.com/writerofscratch/status/1299513347960963072